BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol. 2017;8:561. [PMID: 28878676 DOI: 10.3389/fphar.2017.00561] [Cited by in Crossref: 625] [Cited by in F6Publishing: 535] [Article Influence: 156.3] [Reference Citation Analysis]
Number Citing Articles
1 Bastaki S, Irandoust M, Ahmadi A, Hojjat-Farsangi M, Ambrose P, Hallaj S, Edalati M, Ghalamfarsa G, Azizi G, Yousefi M, Chalajour H, Jadidi-Niaragh F. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. Life Sci 2020;247:117437. [PMID: 32070710 DOI: 10.1016/j.lfs.2020.117437] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
2 Wang M, Wang B, Fang W. CD8+ T-cell percentage increases in diffuse large B-cell lymphoma patients receiving mannatide combined with standard regimens. J Clin Pharm Ther 2021;46:832-7. [PMID: 33569786 DOI: 10.1111/jcpt.13370] [Reference Citation Analysis]
3 Choo YW, Kang M, Kim HY, Han J, Kang S, Lee JR, Jeong GJ, Kwon SP, Song SY, Go S, Jung M, Hong J, Kim BS. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. ACS Nano 2018;12:8977-93. [PMID: 30133260 DOI: 10.1021/acsnano.8b02446] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 31.3] [Reference Citation Analysis]
4 Liu X, He S, Wu H, Xie H, Zhang T, Deng Z. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Environ Health Prev Med 2019;24:79. [PMID: 31864288 DOI: 10.1186/s12199-019-0835-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Loilome W, Dokduang H, Suksawat M, Padthaisong S. Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma. Expert Opin Investig Drugs 2021;:1-22. [PMID: 34292795 DOI: 10.1080/13543784.2021.1955102] [Reference Citation Analysis]
6 Eddy K, Chen S. Overcoming Immune Evasion in Melanoma. Int J Mol Sci 2020;21:E8984. [PMID: 33256089 DOI: 10.3390/ijms21238984] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
7 Tseng CH, Fang WL, Huang KH, Chen MH, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach. J Chin Med Assoc 2020;83:141-7. [PMID: 32015267 DOI: 10.1097/JCMA.0000000000000232] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
8 Yang Y, Nam GH, Kim GB, Kim YK, Kim IS. Intrinsic cancer vaccination. Adv Drug Deliv Rev 2019;151-152:2-22. [PMID: 31132376 DOI: 10.1016/j.addr.2019.05.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
9 Ali AS, Langer SW, Federspiel B, Hjortland GO, Grønbæk H, Ladekarl M, Welin S, Weber Vestermark L, Arola J, Osterlund P, Knigge U, Sørbye H, Micke P, Grimelius L, Grönberg M, Tiensuu Janson E. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS One 2020;15:e0243900. [PMID: 33315908 DOI: 10.1371/journal.pone.0243900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Nemes K, Frühwald MC. Emerging therapeutic targets for the treatment of malignant rhabdoid tumors. Expert Opin Ther Targets 2018;22:365-79. [PMID: 29528755 DOI: 10.1080/14728222.2018.1451839] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
11 Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, Mao Y, Sang X, Seery S, Zhao H. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol 2019;12:42. [PMID: 31014381 DOI: 10.1186/s13045-019-0730-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
12 Schofield M. Current state of the art in continuous bioprocessing. Biotechnol Lett 2018;40:1303-9. [DOI: 10.1007/s10529-018-2593-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
13 Qian J, Wang C, Wang B, Yang J, Wang Y, Luo F, Xu J, Zhao C, Liu R, Chu Y. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation 2018;15:290. [PMID: 30333036 DOI: 10.1186/s12974-018-1330-2] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 19.7] [Reference Citation Analysis]
14 Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175-196. [PMID: 30622344 DOI: 10.1038/s41573-018-0006-z] [Cited by in Crossref: 508] [Cited by in F6Publishing: 386] [Article Influence: 254.0] [Reference Citation Analysis]
15 Smith ME, Farahani SJ, Chao T, Palmer M, Arriola A, Lal P. PD-L1 Positivity Associated With Presence of Tertiary Lymphoid Structures and High-Stage Disease in Upper Tract Urothelial Carcinoma. Am J Clin Pathol 2020;154:802-10. [PMID: 32864684 DOI: 10.1093/ajcp/aqaa105] [Reference Citation Analysis]
16 Jensen AWP, Carnaz Simões AM, Thor Straten P, Holmen Olofsson G. Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe? Cancers (Basel) 2021;13:394. [PMID: 33494360 DOI: 10.3390/cancers13030394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Takeda Y, Azuma M, Funami K, Shime H, Matsumoto M, Seya T. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide. Front Immunol 2018;9:496. [PMID: 29593736 DOI: 10.3389/fimmu.2018.00496] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
18 Fong LWR, Yang DC, Chen CH. Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers. Cancer Metastasis Rev. 2017;36:737-747. [PMID: 29039083 DOI: 10.1007/s10555-017-9709-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
19 Wu Z, Liu J, Dai R, Wu S. Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci 2021;64:512-33. [PMID: 32926318 DOI: 10.1007/s11427-020-1768-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Blaszczak W, Liu G, Zhu H, Barczak W, Shrestha A, Albayrak G, Zheng S, Kerr D, Samsonova A, La Thangue NB. Immune modulation underpins the anti-cancer activity of HDAC inhibitors. Mol Oncol 2021. [PMID: 33773029 DOI: 10.1002/1878-0261.12953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Steeneck C, Kinzel O, Anderhub S, Hornberger M, Pinto S, Morschhaeuser B, Braun F, Kleymann G, Hoffmann T. Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation. ACS Med Chem Lett 2020;11:179-87. [PMID: 32071686 DOI: 10.1021/acsmedchemlett.9b00572] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
22 Xu JZ, Gong C, Xie ZF, Zhao H. Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma. Front Oncol 2020;10:593022. [PMID: 33585210 DOI: 10.3389/fonc.2020.593022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Jiang F, Miao XL, Zhang XT, Yan F, Mao Y, Wu CY, Zhou GP. A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children. J Immunol Res 2021;2021:5523832. [PMID: 34337075 DOI: 10.1155/2021/5523832] [Reference Citation Analysis]
24 Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, Lee JH, Rabizadeh S, Soon-Shiong P, Schlom J, Hodge JW. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer 2020;8:e000450. [PMID: 32439799 DOI: 10.1136/jitc-2019-000450] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 24.0] [Reference Citation Analysis]
25 Goldfarb JA, Dinoi G, Mariani A, Langstraat CL. A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab. Gynecol Oncol Rep 2020;32:100574. [PMID: 32395603 DOI: 10.1016/j.gore.2020.100574] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
26 Minami Y, Nishida N, Kudo M. Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy. Eur Radiol. 2019;29:5045-5051. [PMID: 30963271 DOI: 10.1007/s00330-019-06189-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
27 Payandeh Z, Khalili S, Somi MH, Mard-Soltani M, Baghbanzadeh A, Hajiasgharzadeh K, Samadi N, Baradaran B. PD-1/PD-L1-dependent immune response in colorectal cancer. J Cell Physiol 2020;235:5461-75. [PMID: 31960962 DOI: 10.1002/jcp.29494] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 28.0] [Reference Citation Analysis]
28 Elshimali YI, Wu Y, Khaddour H, Wu Y, Gradinaru D, Sukhija H, Chung SS, Vadgama JV. Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 2018;1:107. [PMID: 29932172 DOI: 10.31021/jcro.20181107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
29 Lin Y, Chen Z, Hu C, Chen Z, Zhang L. Recent progress in antitumor functions of the intracellular antibodies. Drug Discovery Today 2020;25:1109-20. [DOI: 10.1016/j.drudis.2020.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Menter T, Tzankov A. Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy. Virchows Arch 2019;474:497-509. [DOI: 10.1007/s00428-018-2438-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
31 Mehdizadeh S, Bayatipoor H, Pashangzadeh S, Jafarpour R, Shojaei Z, Motallebnezhad M. Immune checkpoints and cancer development: Therapeutic implications and future directions. Pathol Res Pract 2021;223:153485. [PMID: 34022684 DOI: 10.1016/j.prp.2021.153485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Prasanna T, Wu F, Khanna KK, Yip D, Malik L, Dahlstrom JE, Rao S. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy. Cancer Sci 2018;109:3383-92. [PMID: 30230653 DOI: 10.1111/cas.13799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
33 Conesa-Milián L, Falomir E, Murga J, Carda M, Marco JA. Novel multitarget inhibitors with antiangiogenic and immunomodulator properties. Eur J Med Chem 2019;170:87-98. [PMID: 30878834 DOI: 10.1016/j.ejmech.2019.03.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Wang M, Liu Y, Cheng Y, Wei Y, Wei X. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochim Biophys Acta Rev Cancer. 2019;1871:199-224. [PMID: 30605718 DOI: 10.1016/j.bbcan.2018.12.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
35 Qin M, Cao Q, Wu X, Liu C, Zheng S, Xie H, Tian Y, Xie J, Zhao Y, Hou Y, Zhang X, Xu B, Zhang H, Wang X. Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold. European Journal of Medicinal Chemistry 2020;186:111856. [DOI: 10.1016/j.ejmech.2019.111856] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
36 Chen L, Zhou L, Wang C, Han Y, Lu Y, Liu J, Hu X, Yao T, Lin Y, Liang S, Shi S, Dong C. Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers. Adv Mater. 2019;31:e1904997. [PMID: 31721331 DOI: 10.1002/adma.201904997] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 42.5] [Reference Citation Analysis]
37 Felsenstein M, Blank A, Bungert AD, Mueller A, Ghori A, Kremenetskaia I, Rung O, Broggini T, Turkowski K, Scherschinski L, Raggatz J, Vajkoczy P, Brandenburg S. CCR2 of Tumor Microenvironmental Cells Is a Relevant Modulator of Glioma Biology. Cancers (Basel) 2020;12:E1882. [PMID: 32668709 DOI: 10.3390/cancers12071882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Shen M, Kang Y. Complex interplay between tumor microenvironment and cancer therapy. Front Med 2018;12:426-39. [PMID: 30097962 DOI: 10.1007/s11684-018-0663-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
39 Jerome RN, Joly MM, Kennedy N, Shirey-Rice JK, Roden DM, Bernard GR, Holroyd KJ, Denny JC, Pulley JM. Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. Drug Saf 2020;43:567-82. [PMID: 32112228 DOI: 10.1007/s40264-020-00915-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Song H, Liu Y, Li X, Chen S, Xie R, Chen D, Gao H, Wang G, Cai B, Yang X. Long noncoding RNA CASC11 promotes hepatocarcinogenesis and HCC progression through EIF4A3-mediated E2F1 activation. Clin Transl Med 2020;10:e220. [PMID: 33252856 DOI: 10.1002/ctm2.220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
41 Arab A, Yazdian-Robati R, Behravan J. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. Arch Immunol Ther Exp (Warsz) 2020;68:2. [PMID: 31915932 DOI: 10.1007/s00005-019-00566-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
42 Crisci S, Di Francia R, Mele S, Vitale P, Ronga G, De Filippi R, Berretta M, Rossi P, Pinto A. Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Front Oncol 2019;9:443. [PMID: 31214498 DOI: 10.3389/fonc.2019.00443] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
43 Elbæk MV, Pedersen MØ, Breinholt MF, Reddy A, Love C, Clasen‐linde E, Knudsen H, Nielsen SL, Gang AO, Høgdall E, Dave S, Nørgaard P. PD‐L1 expression is low in large B‐cell lymphoma with MYC or double‐hit translocation. Hematological Oncology 2019;37:375-82. [DOI: 10.1002/hon.2664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
44 Wang M, Wang J, Wang R, Jiao S, Wang S, Zhang J, Zhang M. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. Commun Biol 2019;2:392. [PMID: 31667366 DOI: 10.1038/s42003-019-0642-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
45 Albrecht T, Brinkmann F, Albrecht M, Lonsdorf AS, Mehrabi A, Hoffmann K, Kulu Y, Charbel A, Vogel MN, Rupp C, Köhler B, Springfeld C, Schirmacher P, Roessler S, Goeppert B. Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. Cancers (Basel) 2021;13:1682. [PMID: 33918309 DOI: 10.3390/cancers13071682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Backus KM, Cao J, Maddox SM. Opportunities and challenges for the development of covalent chemical immunomodulators. Bioorg Med Chem 2019;27:3421-39. [PMID: 31204229 DOI: 10.1016/j.bmc.2019.05.050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
47 Vesterinen T, Kuopio T, Ahtiainen M, Knuuttila A, Mustonen H, Salmenkivi K, Arola J, Haglund C. PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread. Endocr Connect 2019;8:1168-75. [PMID: 31299636 DOI: 10.1530/EC-19-0308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
48 Li Q, Huang Y. Mitochondrial targeted strategies and their application for cancer and other diseases treatment. J Pharm Investig 2020;50:271-93. [DOI: 10.1007/s40005-020-00481-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
49 Chauhan P, Lokensgard JR. Glial Cell Expression of PD-L1. Int J Mol Sci 2019;20:E1677. [PMID: 30987269 DOI: 10.3390/ijms20071677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
50 Caserta S, Innao V, Musolino C, Allegra A. Immune checkpoint inhibitors in multiple myeloma: A review of the literature. Pathol Res Pract 2020;216:153114. [PMID: 32853951 DOI: 10.1016/j.prp.2020.153114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Caruntu A, Scheau C, Tampa M, Georgescu SR, Caruntu C, Tanase C. Complex Interaction Among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma. Adv Exp Med Biol 2021. [PMID: 33650087 DOI: 10.1007/5584_2021_626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Chang WH, Cerione RA, Antonyak MA. Extracellular Vesicles and Their Roles in Cancer Progression. Methods Mol Biol 2021;2174:143-70. [PMID: 32813249 DOI: 10.1007/978-1-0716-0759-6_10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients 2021;13:1718. [PMID: 34069461 DOI: 10.3390/nu13051718] [Reference Citation Analysis]
54 Lee GA, Lin WL, Kuo DP, Li YT, Chang YW, Chen YC, Huang SW, Hsu JB, Chen CY. Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide. Int J Nanomedicine 2021;16:5233-46. [PMID: 34366665 DOI: 10.2147/IJN.S310464] [Reference Citation Analysis]
55 Chen C, Zuo W, Yang P, Zhang Y. Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report. J Int Med Res 2020;48:300060520951395. [PMID: 32883128 DOI: 10.1177/0300060520951395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
56 Ma C, Luo H, Cao J, Zheng X, Zhang J, Zhang Y, Fu Z. Identification of a Novel Tumor Microenvironment-Associated Eight-Gene Signature for Prognosis Prediction in Lung Adenocarcinoma. Front Mol Biosci 2020;7:571641. [PMID: 33102522 DOI: 10.3389/fmolb.2020.571641] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 8.0] [Reference Citation Analysis]
57 Pavelek Z, Angelucci F, Souček O, Krejsek J, Sobíšek L, Klímová B, Šarláková J, Halúsková S, Kuča K, Vališ M. Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase. J Clin Med 2020;9:E1468. [PMID: 32422897 DOI: 10.3390/jcm9051468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Bhise K, Sau S, Kebriaei R, Rice SA, Stamper KC, Alsaab HO, Rybak MJ, Iyer AK. Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA. Materials (Basel) 2018;11:E1245. [PMID: 30036944 DOI: 10.3390/ma11071245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
59 Sahu P, Kashaw SK, Sau S, Kushwah V, Jain S, Agrawal RK, Iyer AK. pH Responsive 5-Fluorouracil Loaded Biocompatible Nanogels For Topical Chemotherapy of Aggressive Melanoma. Colloids Surf B Biointerfaces 2019;174:232-45. [PMID: 30465998 DOI: 10.1016/j.colsurfb.2018.11.018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
60 Ordikhani F, Uehara M, Kasinath V, Dai L, Eskandari SK, Bahmani B, Yonar M, Azzi JR, Haik Y, Sage PT, Murphy GF, Annabi N, Schatton T, Guleria I, Abdi R. Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. JCI Insight 2018;3:122700. [PMID: 30333312 DOI: 10.1172/jci.insight.122700] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
61 Patel RP, Parikh R, Gunturu KS, Tariq RZ, Dani SS, Ganatra S, Nohria A. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Oncol Rep 2021;23:79. [PMID: 33937956 DOI: 10.1007/s11912-021-01070-6] [Reference Citation Analysis]
62 Wang L, Liu Z, Zhang W, Zhang A, Qu P. PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis. Biomed Res Int 2021;2021:9923434. [PMID: 34124265 DOI: 10.1155/2021/9923434] [Reference Citation Analysis]
63 Singh L, Singh MK, Rizvi MA, Bakhshi S, Meel R, Lomi N, Sen S, Kashyap S. Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma. Cancer Immunol Immunother 2020;69:1087-99. [PMID: 32100078 DOI: 10.1007/s00262-020-02529-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
64 Takeda Y, Yoshida S, Takashima K, Ishii-Mugikura N, Shime H, Seya T, Matsumoto M. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models. Cancer Sci 2018;109:2119-29. [PMID: 29791768 DOI: 10.1111/cas.13649] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
65 Darwish M, Wichner S, Li J, Chang JC, Tam C, Franke Y, Li H, Chan P, Blanchette C. High-throughput identification of conditional MHCI ligands and scaled-up production of conditional MHCI complexes. Protein Sci 2021;30:1169-83. [PMID: 33840137 DOI: 10.1002/pro.4082] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Kamińska-Winciorek G, Cybulska-Stopa B, Lugowska I, Ziobro M, Rutkowski P. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. Postepy Dermatol Alergol 2019;36:382-91. [PMID: 31616210 DOI: 10.5114/ada.2018.80272] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
67 Liu W, Zhang L, Xiu Z, Guo J, Wang L, Zhou Y, Jiao Y, Sun M, Cai J. Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer. Onco Targets Ther 2020;13:7229-41. [PMID: 32801752 DOI: 10.2147/OTT.S255491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
68 Fang WL, Chen MH, Huang KH, Lin CH, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery. Cancers (Basel). 2020;12. [PMID: 32531970 DOI: 10.3390/cancers12061517] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
69 Irie K, Okada A, Yamasaki Y, Kokan C, Hata A, Kaji R, Fukushima K, Sugioka N, Okada Y, Katakami N, Fukushima S. An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 2018;40:716-24. [DOI: 10.1097/ftd.0000000000000558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
70 Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 2018;6:92. [PMID: 29789015 DOI: 10.1186/s40168-018-0483-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 26.3] [Reference Citation Analysis]
71 Pan S, Jiang J, Chen Z, Yang L. Management and Thinking on the Treatment of Cancer Patients During the COVID-19. Front Mol Biosci 2021;8:673360. [PMID: 34277701 DOI: 10.3389/fmolb.2021.673360] [Reference Citation Analysis]
72 Noël G, Langouo Fontsa M, Willard-Gallo K. The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer. Semin Cancer Biol 2018;52:66-74. [PMID: 29574171 DOI: 10.1016/j.semcancer.2018.03.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
73 Stevenson VB, Perry SN, Todd M, Huckle WR, LeRoith T. PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma. Vet Pathol 2021;58:692-8. [PMID: 34169800 DOI: 10.1177/03009858211011939] [Reference Citation Analysis]
74 Chen X, Gao C. Influences of surface coating of PLGA nanoparticles on immune activation of macrophages. J Mater Chem B 2018;6:2065-77. [DOI: 10.1039/c7tb03080k] [Cited by in Crossref: 11] [Article Influence: 3.7] [Reference Citation Analysis]
75 Awi NJ, Teow SY. Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now? J Pathog 2018;2018:8724549. [PMID: 29973995 DOI: 10.1155/2018/8724549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
76 Natarajan A, Patel CB, Ramakrishnan S, Panesar PS, Long SR, Gambhir SS. A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues. Clin Cancer Res 2019;25:1774-85. [PMID: 30373750 DOI: 10.1158/1078-0432.CCR-18-1871] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
77 Alzhrani R, Alsaab HO, Petrovici A, Bhise K, Vanamala K, Sau S, Krinock MJ, Iyer AK. Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems. Drug Discov Today 2020;25:718-30. [PMID: 31758914 DOI: 10.1016/j.drudis.2019.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
78 Gu W, Wang L, Wu Y, Liu JP. Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. Clin Exp Pharmacol Physiol 2019;46:105-15. [PMID: 30565707 DOI: 10.1111/1440-1681.13056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
79 Wu M, Shen J. From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions. Front Oncol 2019;9:1307. [PMID: 31824865 DOI: 10.3389/fonc.2019.01307] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
80 Wang SH, Yu J. Structure-based design for binding peptides in anti-cancer therapy. Biomaterials 2018;156:1-15. [PMID: 29182932 DOI: 10.1016/j.biomaterials.2017.11.024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
81 Yousef S, Alsaab HO, Sau S, Iyer AK. Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma. Heliyon 2018;4:e01071. [PMID: 30603704 DOI: 10.1016/j.heliyon.2018.e01071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
82 Wang LQ, Kumar S, Calin GA, Li Z, Chim CS. Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. Br J Haematol 2020;190:249-61. [PMID: 32079038 DOI: 10.1111/bjh.16517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
83 Deng H, Tan S, Gao X, Zou C, Xu C, Tu K, Song Q, Fan F, Huang W, Zhang Z. Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. Acta Pharm Sin B 2020;10:358-73. [PMID: 32082979 DOI: 10.1016/j.apsb.2019.07.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
84 Segovia-Mendoza M, Romero-Garcia S, Lemini C, Prado-Garcia H. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. J Immunol Res 2021;2021:6668573. [PMID: 33506060 DOI: 10.1155/2021/6668573] [Reference Citation Analysis]
85 Zhu W, Bai Y, Zhang N, Yan J, Chen J, He Z, Sun Q, Pu Y, He B, Ye X. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer. J Mater Chem B 2021;9:4201-10. [PMID: 33997867 DOI: 10.1039/d1tb00537e] [Reference Citation Analysis]
86 D'Alise AM, Leoni G, Cotugno G, Troise F, Langone F, Fichera I, De Lucia M, Avalle L, Vitale R, Leuzzi A, Bignone V, Di Matteo E, Tucci FG, Poli V, Lahm A, Catanese MT, Folgori A, Colloca S, Nicosia A, Scarselli E. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. Nat Commun 2019;10:2688. [PMID: 31217437 DOI: 10.1038/s41467-019-10594-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
87 Murata Y, Tanaka D, Hazama D, Yanagita T, Saito Y, Kotani T, Oldenborg PA, Matozaki T. Anti-human SIRPα antibody is a new tool for cancer immunotherapy. Cancer Sci 2018;109:1300-8. [PMID: 29473266 DOI: 10.1111/cas.13548] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
88 van Schaik TA, Chen KS, Shah K. Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy? Front Oncol 2021;11:678562. [PMID: 34141622 DOI: 10.3389/fonc.2021.678562] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Bode AM, Dong Z. Recent advances in precision oncology research. NPJ Precis Oncol 2018;2:11. [PMID: 30202789 DOI: 10.1038/s41698-018-0055-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
90 Nesic M, Sønderkær M, Brøndum RF, El-Galaly TC, Pedersen IS, Bøgsted M, Dybkær K. The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. BMC Cancer 2021;21:829. [PMID: 34275438 DOI: 10.1186/s12885-021-08556-3] [Reference Citation Analysis]
91 Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, Li P, Lyu N, Sun T, Xie S, Guo L, Ni L, Jin L, Dong C. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol 2020;17:227-36. [PMID: 31611650 DOI: 10.1038/s41423-019-0305-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
92 Saxena R, Wang Y, Mier JW. CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors. Melanoma Res 2020;30:14-25. [PMID: 31524789 DOI: 10.1097/CMR.0000000000000639] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
93 Alwithenani A, Bethune D, Castonguay M, Drucker A, Flowerdew G, Forsythe M, French D, Fris J, Greer W, Henteleff H, MacNeil M, Marignani P, Morzycki W, Plourde M, Snow S, Marcato P, Xu Z. Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR. PLoS One 2021;16:e0251080. [PMID: 33956842 DOI: 10.1371/journal.pone.0251080] [Reference Citation Analysis]
94 Wang S, Zhu H, Ding J, Wang F, Meng X, Ding L, Zhang Y, Li N, Yao S, Sheng X, Yang Z. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study. Clin Nucl Med 2021;46:382-8. [PMID: 33512952 DOI: 10.1097/RLU.0000000000003520] [Reference Citation Analysis]
95 Wu A, Zhang S, Liu J, Huang Y, Deng W, Shu G, Yin G. Integrated Analysis of Prognostic and Immune Associated Integrin Family in Ovarian Cancer. Front Genet 2020;11:705. [PMID: 32765584 DOI: 10.3389/fgene.2020.00705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
96 Maghrouni A, Givari M, Jalili-Nik M, Mollazadeh H, Bibak B, Sadeghi MM, Afshari AR, Johnston TP, Sahebkar A. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. Int Immunopharmacol 2021;93:107403. [PMID: 33581502 DOI: 10.1016/j.intimp.2021.107403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Ge S, Zhong H, Ma X, Zheng Y, Zou Y, Wang F, Wang Y, Hu Y, Li Y, Liu W, Guo W, Xu Q, Lai Y. Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo. J Enzyme Inhib Med Chem 2020;35:1240-57. [PMID: 32466694 DOI: 10.1080/14756366.2020.1765165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
98 Wang X, Liu S, Zhao X, Fang E, Zhao X. The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: A meta-analysis. PLoS One 2019;14:e0219215. [PMID: 31260491 DOI: 10.1371/journal.pone.0219215] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
99 Grimaldi AM, Salvatore M, Incoronato M. miRNA-Based Therapeutics in Breast Cancer: A Systematic Review. Front Oncol 2021;11:668464. [PMID: 34026646 DOI: 10.3389/fonc.2021.668464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
100 Shen X, Zhao Y, Liu G, Zhou H, Fan J, Zhang L, Li Y, Wang Y, Liang J, Xu Z. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer. Life Sciences 2020;256:117923. [DOI: 10.1016/j.lfs.2020.117923] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
101 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
102 Baleydier F, Bernard F, Ansari M. The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers. Biomolecules 2020;10:E1112. [PMID: 32731356 DOI: 10.3390/biom10081112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Li D, Deng Y, Achab A, Bharathan I, Hopkins BA, Yu W, Zhang H, Sanyal S, Pu Q, Zhou H, Liu K, Lim J, Fradera X, Lesburg CA, Lammens A, Martinot TA, Cohen RD, Doty AC, Ferguson H, Nickbarg EB, Cheng M, Spacciapoli P, Geda P, Song X, Smotrov N, Abeywickrema P, Andrews C, Chamberlin C, Mabrouk O, Curran P, Richards M, Saradjian P, Miller JR, Knemeyer I, Otte KM, Vincent S, Sciammetta N, Pasternak A, Bennett DJ, Han Y. Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors. ACS Med Chem Lett 2021;12:389-96. [PMID: 33738066 DOI: 10.1021/acsmedchemlett.0c00525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
104 Yun K, Daniels G, Gold K, Mccowen K, Patel SP. Rapid onset type 1 diabetes with anti-PD-1 directed therapy. Oncotarget 2020;11:2740-6. [PMID: 32733645 DOI: 10.18632/oncotarget.27665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Pu Q, Zhang H, Guo L, Cheng M, Doty AC, Ferguson H, Fradera X, Lesburg CA, McGowan MA, Miller JR, Geda P, Song X, Otte K, Sciammetta N, Solban N, Yu W, Sloman DL, Zhou H, Lammens A, Neumann L, Bennett DJ, Pasternak A, Han Y. Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors. ACS Med Chem Lett 2020;11:1548-54. [PMID: 32832022 DOI: 10.1021/acsmedchemlett.0c00195] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
106 Zhu S, Lv X, Zhang X, Li T, Zang G, Yang N, Wang X, Wu J, Chen W, Liu YJ, Chen J. An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma. Int J Cancer 2019;144:2867-79. [PMID: 30565657 DOI: 10.1002/ijc.32008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
107 Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol 2019;16:539-52. [DOI: 10.1038/s41585-019-0211-5] [Cited by in Crossref: 87] [Cited by in F6Publishing: 67] [Article Influence: 43.5] [Reference Citation Analysis]
108 Yao L, Jia G, Lu L, Bao Y, Ma W. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. International Immunopharmacology 2020;85:106628. [DOI: 10.1016/j.intimp.2020.106628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
109 Wong J, Choi SYC, Liu R, Xu E, Killam J, Gout PW, Wang Y. Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells. Front Cell Infect Microbiol 2019;9:25. [PMID: 30809511 DOI: 10.3389/fcimb.2019.00025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
110 Chen RQ, Liu F, Qiu XY, Chen XQ. The Prognostic and Therapeutic Value of PD-L1 in Glioma. Front Pharmacol 2018;9:1503. [PMID: 30687086 DOI: 10.3389/fphar.2018.01503] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 17.0] [Reference Citation Analysis]
111 Liu X, Shan C, Song Y, Du J. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Front Oncol 2019;9:1111. [PMID: 31709181 DOI: 10.3389/fonc.2019.01111] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
112 Akella P, Loganathan S, Jindal V, Akhtar J, Lal A. Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series. Respir Med Case Rep 2019;26:17-22. [PMID: 30456167 DOI: 10.1016/j.rmcr.2018.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
113 Gulla SK, Kotcherlakota R, Nimushakavi S, Nimmu NV, Khalid S, Patra CR, Chaudhuri A. Au-CGKRK Nanoconjugates for Combating Cancer through T-Cell-Driven Therapeutic RNA Interference. ACS Omega 2018;3:8663-76. [PMID: 31458997 DOI: 10.1021/acsomega.8b01051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
114 Sanaei MJ, Pourbagheri-Sigaroodi A, Kaveh V, Abolghasemi H, Ghaffari SH, Momeny M, Bashash D. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. Eur J Pharmacol 2021;909:174404. [PMID: 34363829 DOI: 10.1016/j.ejphar.2021.174404] [Reference Citation Analysis]
115 Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev 2019;78:8-16. [PMID: 31302573 DOI: 10.1016/j.ctrv.2019.07.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
116 Takaki H, Hirata Y, Ueshima E, Kodama H, Matsumoto S, Wada R, Suzuki H, Nakasho K, Yamakado K. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation. J Vasc Interv Radiol 2020;31:1475-1482.e2. [PMID: 32800663 DOI: 10.1016/j.jvir.2020.03.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Aghajani MJ, Roberts TL, Yang T, McCafferty CE, Caixeiro NJ, DeSouza P, Niles N. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. Endocr Connect 2019;8:1040-51. [PMID: 31252406 DOI: 10.1530/EC-19-0210] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
118 Zhang SC, Hu ZQ, Long JH, Zhu GM, Wang Y, Jia Y, Zhou J, Ouyang Y, Zeng Z. Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer. J Cancer 2019;10:6175-84. [PMID: 31762828 DOI: 10.7150/jca.35901] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
119 Power Coombs MR, Hoskin DW. Assessing the Impact of Phytochemicals on Immune Checkpoints: Implications for Cancer Immunotherapy. Methods Mol Biol 2020;2111:161-73. [PMID: 31933207 DOI: 10.1007/978-1-0716-0266-9_14] [Reference Citation Analysis]
120 Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The Identification of Immunological Biomarkers in Kidney Cancers. Front Oncol 2018;8:456. [PMID: 30450335 DOI: 10.3389/fonc.2018.00456] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
121 Wang P, Wang T, Yang Y, Yu C, Liu N, Yan C. Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas: A case report and review of the literatures. Medicine (Baltimore) 2017;96:e9056. [PMID: 29245312 DOI: 10.1097/MD.0000000000009056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
122 Qin M, Cao Q, Zheng S, Tian Y, Zhang H, Xie J, Xie H, Liu Y, Zhao Y, Gong P. Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. J Med Chem 2019;62:4703-15. [PMID: 30964291 DOI: 10.1021/acs.jmedchem.9b00312] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
123 Hosseini M, Amjadi I, Mohajeri M, Iqbal MZ, Wu A, Mozafari M. Functionalized polymers for diagnostic engineering. Advanced Functional Polymers for Biomedical Applications. Elsevier; 2019. pp. 301-22. [DOI: 10.1016/b978-0-12-816349-8.00015-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
124 Konen JM, Fradette JJ, Gibbons DL. The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors. Cells 2019;9:E52. [PMID: 31878283 DOI: 10.3390/cells9010052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
125 Biteghe FAN, Mungra N, Chalomie NET, Ndong JC, Engohang-Ndong J, Vignaux G, Padayachee E, Naran K, Barth S. Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies. Oncotarget 2020;11:3531-57. [PMID: 33014289 DOI: 10.18632/oncotarget.27730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
126 Han S, Toker A, Liu ZQ, Ohashi PS. Turning the Tide Against Regulatory T Cells. Front Oncol 2019;9:279. [PMID: 31058083 DOI: 10.3389/fonc.2019.00279] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
127 Agupitan AD, Neeson P, Williams S, Howitt J, Haupt S, Haupt Y. P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. Int J Mol Sci 2020;21:E3452. [PMID: 32414156 DOI: 10.3390/ijms21103452] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
128 Sun H, Chen D, Zhan S, Wu W, Xu H, Luo C, Su H, Feng Y, Shao W, Wan A, Zhou B, Wan G, Bu X. Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand 1 Inhibitor as Immune Modulator for Cancer Therapy. J Med Chem 2020;63:11286-301. [PMID: 32844651 DOI: 10.1021/acs.jmedchem.0c01262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
129 Gilmore E, McCabe N, Kennedy RD, Parkes EE. DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. J Oncol 2019;2019:4325105. [PMID: 31320901 DOI: 10.1155/2019/4325105] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
130 Shi J, Hou Z, Yan J, Qiu W, Liang L, Meng M, Li L, Wang X, Xie Y, Jiang L, Wang W. The prognostic significance of fibroblast activation protein-α in human lung adenocarcinoma. Ann Transl Med 2020;8:224. [PMID: 32309371 DOI: 10.21037/atm.2020.01.82] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
131 Alsaab HO, Sau S, Alzhrani RM, Cheriyan VT, Polin LA, Vaishampayan U, Rishi AK, Iyer AK. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 2018;183:280-94. [PMID: 30179778 DOI: 10.1016/j.biomaterials.2018.08.053] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
132 Lawson NL, Dix CI, Scorer PW, Stubbs CJ, Wong E, Hutchinson L, McCall EJ, Schimpl M, DeVries E, Walker J, Williams GH, Hunt J, Barker C. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Mod Pathol 2020;33:518-30. [PMID: 31558782 DOI: 10.1038/s41379-019-0372-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
133 Murata Y, Saito Y, Kotani T, Matozaki T. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy. Cancer Sci 2018;109:2349-57. [PMID: 29873856 DOI: 10.1111/cas.13663] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 12.7] [Reference Citation Analysis]
134 Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4:611-621. [PMID: 31109808 DOI: 10.1016/s2468-1253(19)30086-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 34] [Article Influence: 37.0] [Reference Citation Analysis]
135 Hsu LW, Huang KH, Chen MH, Fang WL, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. Genetic alterations in gastric cancer patients according to sex. Aging (Albany NY) 2020;13:376-88. [PMID: 33288737 DOI: 10.18632/aging.202142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
136 Varn FS, Schaafsma E, Wang Y, Cheng C. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs. Cancer Res 2018;78:6413-23. [PMID: 30254145 DOI: 10.1158/0008-5472.CAN-18-1342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
137 Ahmadzada T, Lee K, Clarke C, Cooper WA, Linton A, McCaughan B, Asher R, Clarke S, Reid G, Kao S. High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer 2019;130:35-41. [PMID: 30885349 DOI: 10.1016/j.lungcan.2019.02.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
138 Mohty R, Gauthier J. Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. Bone Marrow Transplant 2021. [PMID: 34290380 DOI: 10.1038/s41409-021-01420-9] [Reference Citation Analysis]
139 Manz SM, Losa M, Fritsch R, Scharl M. Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. Therap Adv Gastroenterol 2021;14:17562848211002018. [PMID: 33948110 DOI: 10.1177/17562848211002018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Broos K, Lecocq Q, Keersmaecker B, Raes G, Corthals J, Lion E, Thielemans K, Devoogdt N, Keyaerts M, Breckpot K. Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. Vaccines (Basel) 2019;7:E85. [PMID: 31394834 DOI: 10.3390/vaccines7030085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
141 Chivu-Economescu M, Necula LG, Matei L, Dragu DL, Neagu AI, Alexiu I, Bleotu C, Diaconu CC. Gastrointestinal cancer stem cells as targets for innovative immunotherapy. World J Gastroenterol 2020;26:1580-93. [PMID: 32327907 DOI: 10.3748/wjg.v26.i14.1580] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Karamouzis MV, Papavassiliou AG. Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future. Expert Opin Investig Drugs 2018;27:569-72. [PMID: 29958097 DOI: 10.1080/13543784.2018.1494724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
143 Li J, Wang Y, Jin W, Shen L. Actinidia eriantha Polysaccharide and PD1-Antibody Combination Therapy Enhances Antitumor Efficacy in Colorectal Cancer-Xenograft Mice. Onco Targets Ther 2021;14:1239-48. [PMID: 33658792 DOI: 10.2147/OTT.S294253] [Reference Citation Analysis]
144 Papademetrio DL, Garcia MN, Grasso D, Alvarez É. Autophagy-Mediated Exosomes as Immunomodulators of Natural Killer Cells in Pancreatic Cancer Microenvironment. Front Oncol 2020;10:622956. [PMID: 33680945 DOI: 10.3389/fonc.2020.622956] [Reference Citation Analysis]
145 Ye D, Yuan J, Yue Y, Rubin JB, Chen H. Focused Ultrasound-Enhanced Delivery of Intranasally Administered Anti-Programmed Cell Death-Ligand 1 Antibody to an Intracranial Murine Glioma Model. Pharmaceutics 2021;13:190. [PMID: 33535531 DOI: 10.3390/pharmaceutics13020190] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
146 Pham LM, Poudel K, Ou W, Phung CD, Nguyen HT, Nguyen BL, Karmacharya P, Pandit M, Chang JH, Jeong JH, Ku SK, Yong CS, Choi HG, Kim JO. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles. Int J Pharm 2021;605:120816. [PMID: 34161810 DOI: 10.1016/j.ijpharm.2021.120816] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Tomás-Bort E, Kieler M, Sharma S, Candido JB, Loessner D. 3D approaches to model the tumor microenvironment of pancreatic cancer. Theranostics 2020;10:5074-89. [PMID: 32308769 DOI: 10.7150/thno.42441] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 23.0] [Reference Citation Analysis]
148 Lopez AT, Geskin L. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. Oncologist 2018;23:1119-26. [PMID: 30018132 DOI: 10.1634/theoncologist.2018-0128] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
149 Sahu P, Kashaw SK, Sau S, Kushwah V, Jain S, Iyer AK. Discovering pH triggered charge rebound surface modulated topical nanotherapy against aggressive skin papilloma. Mater Sci Eng C Mater Biol Appl 2020;107:110263. [PMID: 31761163 DOI: 10.1016/j.msec.2019.110263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
150 Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front Immunol 2020;11:1986. [PMID: 32983137 DOI: 10.3389/fimmu.2020.01986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
151 Al Homsi MU, Mostafa M, Fahim K. Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy. Case Rep Oncol 2018;11:467-75. [PMID: 30140209 DOI: 10.1159/000490636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
152 Gilardini Montani MS, Santarelli R, Falcinelli L, Gonnella R, Granato M, Di Renzo L, Cuomo L, Vitillo M, Faggioni A, Cirone M. EBV up-regulates PD-L1 on the surface of primary monocytes by increasing ROS and activating TLR signaling and STAT3. J Leukoc Biol 2018;104:821-32. [PMID: 30040158 DOI: 10.1002/JLB.2A0118-029RR] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 6.7] [Reference Citation Analysis]
153 Riesenberg BP, Ansa-Addo EA, Gutierrez J, Timmers CD, Liu B, Li Z. Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 Blockade. J Immunol 2019;203:1105-10. [PMID: 31358658 DOI: 10.4049/jimmunol.1900594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
154 Alsaab HO, Alghamdi MS, Alotaibi AS, Alzhrani R, Alwuthaynani F, Althobaiti YS, Almalki AH, Sau S, Iyer AK. Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine. Cancers (Basel) 2020;12:E2793. [PMID: 33003374 DOI: 10.3390/cancers12102793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 17.0] [Reference Citation Analysis]
155 Daneshmandi S, Wegiel B, Seth P. Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma. Cancers (Basel) 2019;11:E450. [PMID: 30934955 DOI: 10.3390/cancers11040450] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
156 Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Curr Hematol Malig Rep 2020;15:372-81. [PMID: 32394185 DOI: 10.1007/s11899-020-00589-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
157 Musacchio L, Boccia SM, Caruso G, Santangelo G, Fischetti M, Tomao F, Perniola G, Palaia I, Muzii L, Pignata S, Benedetti Panici P, Di Donato V. Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients? J Clin Med 2020;9:E1721. [PMID: 32503218 DOI: 10.3390/jcm9061721] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
158 Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy 2021;13:637-44. [PMID: 33820447 DOI: 10.2217/imt-2021-0026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
159 Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, Estupinian R, Aboelatta MM, Buddhadev S, Tarabichi S, Lee M, Li S, Medina DJ, Giurini EF, Gupta KH, Guevara-Aleman G, Rossi M, Nowicki C, Abed A, Goldufsky JW, Broucek JR, Redondo RE, Rotter D, Jhawar SR, Wang SJ, Kohlhapp FJ, Kaufman HL, Thomas PG, Gupta V, Kuzel TM, Reiser J, Paras J, Kane MP, Singer EA, Malhotra J, Denzin LK, Sant'Angelo DB, Rabson AB, Lee LY, Lasfar A, Langenfeld J, Schenkel JM, Fidler MJ, Ruiz ES, Marzo AL, Rudra JS, Silk AW, Zloza A. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc Natl Acad Sci U S A 2020;117:1119-28. [PMID: 31888983 DOI: 10.1073/pnas.1904022116] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 23.5] [Reference Citation Analysis]
160 Tu K, Deng H, Kong L, Wang Y, Yang T, Hu Q, Hu M, Yang C, Zhang Z. Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death. ACS Appl Mater Interfaces 2020;12:16018-30. [PMID: 32192326 DOI: 10.1021/acsami.9b23084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
161 Fujiwara Y, Iguchi H, Yamamoto N, Hayama M, Nii M, Ueda S, Komuro K, Sugimoto M, Vlahovic G, Kozuki T. Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors. Cancer Sci 2019;110:1715-23. [PMID: 30891877 DOI: 10.1111/cas.14003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
162 Sforzini L, Nettis MA, Mondelli V, Pariante CM. Inflammation in cancer and depression: a starring role for the kynurenine pathway. Psychopharmacology (Berl) 2019;236:2997-3011. [PMID: 30806743 DOI: 10.1007/s00213-019-05200-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
163 Roviello G, Catalano M, Nobili S, Santi R, Mini E, Nesi G. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? Int J Mol Sci 2020;21:E7935. [PMID: 33114616 DOI: 10.3390/ijms21217935] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
164 Yan Y, Zhang L, Zuo Y, Qian H, Liu C. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Arch Immunol Ther Exp 2020;68. [DOI: 10.1007/s00005-020-00601-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
165 Thomas R, Somarouthu B, Alessandrino F, Kurra V, Shinagare AB. Atypical Response Patterns in Patients Treated With Nivolumab. AJR Am J Roentgenol. 2019;1-5. [PMID: 30917022 DOI: 10.2214/ajr.18.20938] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
166 Cosentini D, Grisanti S, Dalla Volta A, Laganà M, Fiorentini C, Perotti P, Sigala S, Berruti A. Immunotherapy failure in adrenocortical cancer: where next? Endocr Connect 2018;7:E5-8. [PMID: 30400026 DOI: 10.1530/EC-18-0398] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 7.7] [Reference Citation Analysis]
167 Wang J, Li Z, Wang Z, Yu Y, Li D, Li B, Ding J. Nanomaterials for Combinational Radio–Immuno Oncotherapy. Adv Funct Mater 2020;30:1910676. [DOI: 10.1002/adfm.201910676] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 17.0] [Reference Citation Analysis]
168 Zafar FS, Richey P, Okereke U, Milhem M, Abid R, Powers JG. Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature. Melanoma Res 2021;31:98-100. [PMID: 33323722 DOI: 10.1097/CMR.0000000000000713] [Reference Citation Analysis]
169 Maimaitiyiming Y, Hong F, Yang C, Naranmandura H. Novel insights into the role of aptamers in the fight against cancer. J Cancer Res Clin Oncol 2019;145:797-810. [PMID: 30830295 DOI: 10.1007/s00432-019-02882-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
170 Hinsch A, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W. Expression of the immune checkpoint receptor TIGIT in seminoma. Oncol Lett 2019;18:1497-502. [PMID: 31423216 DOI: 10.3892/ol.2019.10428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
171 Chen M, Sharma A, Lin Y, Wu Y, He Q, Gu Y, Xu ZP, Monteiro M, Gu W. Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells. BMC Cancer. 2019;19:153. [PMID: 30770752 DOI: 10.1186/s12885-019-5364-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
172 Yang Q, Wang Y, Zhang S, Tang J, Li F, Yin J, Li Y, Fu J, Li B, Luo Y, Xue W, Zhu F. Biomarker Discovery for Immunotherapy of Pituitary Adenomas: Enhanced Robustness and Prediction Ability by Modern Computational Tools. Int J Mol Sci 2019;20:E151. [PMID: 30609812 DOI: 10.3390/ijms20010151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
173 Zhu Z, Dong W. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. Onco Targets Ther 2018;11:1563-70. [PMID: 29593422 DOI: 10.2147/OTT.S160493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
174 Li Y, Qi M, Ding F, Lv Y, Ma J, Zhu Y. Tumour targetable and microenvironment-responsive nanoparticles simultaneously disrupt the PD-1/PD-L1 pathway and MAPK/ERK/JNK pathway for efficient treatment of colorectal cancer. J Drug Target 2021;29:454-65. [PMID: 33233956 DOI: 10.1080/1061186X.2020.1853750] [Reference Citation Analysis]
175 Qi Y, Deng G, Xu P, Zhang H, Yuan F, Geng R, Jiang H, Liu B, Chen Q. HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma. Oncol Rep 2019;42:2309-22. [PMID: 31578594 DOI: 10.3892/or.2019.7343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
176 Sau S, Petrovici A, Alsaab HO, Bhise K, Iyer AK. PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer. Cancers (Basel) 2019;11:E232. [PMID: 30781490 DOI: 10.3390/cancers11020232] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
177 Ye X, Liang X, Chen Q, Miao Q, Chen X, Zhang X, Mei L. Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy. ACS Nano 2019;13:2956-68. [PMID: 30789699 DOI: 10.1021/acsnano.8b07371] [Cited by in Crossref: 103] [Cited by in F6Publishing: 78] [Article Influence: 51.5] [Reference Citation Analysis]
178 Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17:129. [PMID: 30139382 DOI: 10.1186/s12943-018-0864-3] [Cited by in Crossref: 197] [Cited by in F6Publishing: 187] [Article Influence: 65.7] [Reference Citation Analysis]
179 Leone K, Poggiana C, Zamarchi R. The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy. Diagnostics (Basel) 2018;8:E59. [PMID: 30200242 DOI: 10.3390/diagnostics8030059] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
180 Moreno-Vicente J, Beers SA, Gray JC. PD-1/PD-L1 blockade in paediatric cancers: What does the future hold? Cancer Lett 2019;457:74-85. [PMID: 31055109 DOI: 10.1016/j.canlet.2019.04.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
181 Islam MK, Stanslas J. Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer. Pharmacol Ther 2021;227:107870. [PMID: 33895183 DOI: 10.1016/j.pharmthera.2021.107870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Boucherit N, Gorvel L, Olive D. 3D Tumor Models and Their Use for the Testing of Immunotherapies. Front Immunol 2020;11:603640. [PMID: 33362787 DOI: 10.3389/fimmu.2020.603640] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
183 Anderluh M, Berti F, Bzducha-Wróbel A, Chiodo F, Colombo C, Compostella F, Durlik K, Ferhati X, Holmdahl R, Jovanovic D, Kaca W, Lay L, Marinovic-Cincovic M, Marradi M, Ozil M, Polito L, Reina-Martin JJ, Reis CA, Sackstein R, Silipo A, Švajger U, Vaněk O, Yamamoto F, Richichi B, van Vliet SJ. Emerging glyco-based strategies to steer immune responses. FEBS J 2021;288:4746-72. [PMID: 33752265 DOI: 10.1111/febs.15830] [Reference Citation Analysis]
184 Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics 2019;13:14-21. [PMID: 30997392 DOI: 10.1016/j.omto.2019.03.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
185 Chen RQ, Xu XH, Liu F, Li CY, Li YJ, Li XR, Jiang GY, Hu F, Liu D, Pan F, Qiu XY, Chen XQ. The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling. Front Oncol. 2019;9:1347. [PMID: 31850228 DOI: 10.3389/fonc.2019.01347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
186 Routman DM, Garant A, Lester SC, Day CN, Harmsen WS, Sanheuza CT, Yoon HH, Neben-Wittich MA, Martenson JA, Haddock MG, Hallemeier CL, Merrell KW. A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. Adv Radiat Oncol 2019;4:63-9. [PMID: 30706012 DOI: 10.1016/j.adro.2018.09.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
187 Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol 2019;12:126. [PMID: 31779642 DOI: 10.1186/s13045-019-0817-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
188 Robu S, Richter A, Gosmann D, Seidl C, Leung D, Hayes W, Cohen D, Morin P, Donnelly DJ, Lipovšek D, Bonacorsi SJ, Smith A, Steiger K, Aulehner C, Krackhardt AM, Weber WA. Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression. J Nucl Med 2021;62:1228-34. [PMID: 33517324 DOI: 10.2967/jnumed.120.258384] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
189 Kim JH, Kim YS, Choi JG, Li W, Lee EJ, Park JW, Song J, Chung HS. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro. Int J Mol Sci 2020;21:E3239. [PMID: 32375257 DOI: 10.3390/ijms21093239] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
190 Holmen Olofsson G, Jensen AWP, Idorn M, Thor Straten P. Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo. Int J Mol Sci 2020;21:E3816. [PMID: 32471301 DOI: 10.3390/ijms21113816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
191 Li Z, Li X, Lam W, Cao Y, Han H, Zhang X, Fang J, Xiao K, Zhou F. Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials. Front Oncol 2021;11:629646. [PMID: 33869015 DOI: 10.3389/fonc.2021.629646] [Reference Citation Analysis]
192 Xu F, Zhan X, Zheng X, Xu H, Li Y, Huang X, Lin L, Chen Y. A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma. Genomics 2020;112:4675-83. [PMID: 32798715 DOI: 10.1016/j.ygeno.2020.08.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
193 Chung HC, Bang YJ, S Fuchs C, Qin SK, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Alsina M, Cao ZA, Lu J, Bhagia P, Shih CS, Janjigian YY. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol 2021;17:491-501. [PMID: 33167735 DOI: 10.2217/fon-2020-0737] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
194 Liu HJ, Lizotte PH, Du H, Speranza MC, Lam HC, Vaughan S, Alesi N, Wong KK, Freeman GJ, Sharpe AH, Henske EP. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. JCI Insight 2018;3:98674. [PMID: 29669930 DOI: 10.1172/jci.insight.98674] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
195 Blevins DJ, Hanley R, Bolduc T, Powell DA, Gignac M, Walker K, Carr MD, Hof F, Wulff JE. In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action. ACS Med Chem Lett 2019;10:1187-92. [PMID: 31413804 DOI: 10.1021/acsmedchemlett.9b00221] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
196 Dolcino M, Pelosi A, Fiore PF, Patuzzo G, Tinazzi E, Lunardi C, Puccetti A. Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures. Front Immunol 2018;9:449. [PMID: 29559981 DOI: 10.3389/fimmu.2018.00449] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
197 Lin HY, Chin YT, Shih YJ, Chen YR, Leinung M, Keating KA, Mousa SA, Davis PJ. In tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic. Oncotarget 2018;9:34033-7. [PMID: 30344919 DOI: 10.18632/oncotarget.26143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
198 Liao JY, Zhang S. Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. Front Oncol 2021;11:663264. [PMID: 34123821 DOI: 10.3389/fonc.2021.663264] [Reference Citation Analysis]
199 Huang KH, Chen MH, Fang WL, Lin CH, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer. Cancers (Basel) 2020;12:E2318. [PMID: 32824568 DOI: 10.3390/cancers12082318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
200 Erol T, İmamoğlu NE, Aydin B, Taşkiran ZE, Esendağli G, Kösemehmetoğlu K, Baykal A. Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival. Medicine (Baltimore) 2019;98:e16773. [PMID: 31415379 DOI: 10.1097/MD.0000000000016773] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
201 Deng Z, Xu XY, Yunita F, Zhou Q, Wu YR, Hu YX, Wang ZQ, Tian XF. Synergistic anti-liver cancer effects of curcumin and total ginsenosides. World J Gastrointest Oncol 2020;12:1091-103. [PMID: 33133379 DOI: 10.4251/wjgo.v12.i10.1091] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Steeneck C, Kinzel O, Anderhub S, Hornberger M, Pinto S, Morschhaeuser B, Albers M, Sonnek C, Czekańska M, Hoffmann T. Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors. Bioorganic & Medicinal Chemistry Letters 2021;33:127744. [DOI: 10.1016/j.bmcl.2020.127744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
203 Geri JB, Oakley JV, Reyes-Robles T, Wang T, McCarver SJ, White CH, Rodriguez-Rivera FP, Parker DL Jr, Hett EC, Fadeyi OO, Oslund RC, MacMillan DWC. Microenvironment mapping via Dexter energy transfer on immune cells. Science 2020;367:1091-7. [PMID: 32139536 DOI: 10.1126/science.aay4106] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 46.0] [Reference Citation Analysis]
204 Liu X, Cao L, Chin W, Yu J, Liu Y, Zheng S. Epstein-Barr virus-negative inflammatory pseudotumor-like variant of follicular dendritic cell sarcoma of the liver: A case report and literature review. Clin Res Hepatol Gastroenterol 2021;45:101457. [PMID: 32540141 DOI: 10.1016/j.clinre.2020.05.007] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
205 Liao XY, Liu CY, He JF, Wang LS, Zhang T. Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy. Oncol Lett 2019;18:5011-21. [PMID: 31612012 DOI: 10.3892/ol.2019.10893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
206 Piao J, Lim HJ, Lee M. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis. Obstet Gynecol Sci 2020;63:346-56. [PMID: 32489980 DOI: 10.5468/ogs.2020.63.3.346] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
207 Lima BV, Oliveira MJ, Barbosa MA, Gonçalves RM, Castro F. Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies. Biomater Sci 2021;9:3209-27. [PMID: 33949372 DOI: 10.1039/d0bm01984d] [Reference Citation Analysis]
208 Narducci MG, Tosi A, Frezzolini A, Scala E, Passarelli F, Bonmassar L, Monopoli A, Accetturi MP, Cantonetti M, Antonini Cappellini GC, De Galitiis F, Rosato A, Picozza M, Russo G, D'Atri S. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. Front Immunol 2020;11:579894. [PMID: 33072126 DOI: 10.3389/fimmu.2020.579894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
209 Mehdi A, Attias M, Mahmood N, Arakelian A, Mihalcioiu C, Piccirillo CA, Szyf M, Rabbani SA. Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma. Front Oncol 2020;10:1361. [PMID: 32983966 DOI: 10.3389/fonc.2020.01361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
210 Seifert HA, Gerstner G, Kent G, Vandenbark AA, Offner H. Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE. J Neuroinflammation 2019;16:195. [PMID: 31665042 DOI: 10.1186/s12974-019-1588-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
211 Wang H, Mustafa A, Liu S, Liu J, Lv D, Yang H, Zou J. Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. Front Pharmacol 2019;10:1254. [PMID: 31708780 DOI: 10.3389/fphar.2019.01254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
212 Tranberg KG. Local Destruction of Tumors and Systemic Immune Effects. Front Oncol 2021;11:708810. [PMID: 34307177 DOI: 10.3389/fonc.2021.708810] [Reference Citation Analysis]
213 Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Colloids and Surfaces B: Biointerfaces 2018;167:8-19. [DOI: 10.1016/j.colsurfb.2018.03.046] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 15.0] [Reference Citation Analysis]
214 Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci 2021;22:6532. [PMID: 34207103 DOI: 10.3390/ijms22126532] [Reference Citation Analysis]
215 Zhang X, Wang C, Wang J, Hu Q, Langworthy B, Ye Y, Sun W, Lin J, Wang T, Fine J, Cheng H, Dotti G, Huang P, Gu Z. PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy. Adv Mater 2018;30:1707112. [DOI: 10.1002/adma.201707112] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 31.0] [Reference Citation Analysis]
216 Oei SL, Thronicke A, Schad F. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies. Evid Based Complement Alternat Med 2019;2019:5893017. [PMID: 31118962 DOI: 10.1155/2019/5893017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
217 Xue C, Chen X, Lin K, Tong Y, Wang X. Identification of Notch signaling pathway gene mutations as a prognostic biomarker for bladder cancer. Future Oncol 2021. [PMID: 34338007 DOI: 10.2217/fon-2021-0110] [Reference Citation Analysis]
218 Hoeres T, Holzmann E, Smetak M, Birkmann J, Wilhelm M. PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-Cells in response to leukemia. Oncoimmunology 2019;8:1550618. [PMID: 30723581 DOI: 10.1080/2162402X.2018.1550618] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 9.3] [Reference Citation Analysis]
219 Lilly E, El Gharib K. Immunotherapy and non-muscle-invasive bladder cancer: an idea from the 19th century. Expert Rev Anticancer Ther 2021;21:689-92. [PMID: 33882763 DOI: 10.1080/14737140.2021.1921578] [Reference Citation Analysis]
220 Rao AA, Madejska AA, Pfeil J, Paten B, Salama SR, Haussler D. ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy. Front Immunol 2020;11:483296. [PMID: 33244314 DOI: 10.3389/fimmu.2020.483296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Chen Y, Gao M, Huang Z, Yu J, Meng X. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol 2020;13:105. [PMID: 32723363 DOI: 10.1186/s13045-020-00940-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
222 Ohno Y, Ohshima S, Miyamoto A, Kametani F, Ito R, Tsuda B, Kasama Y, Nakada S, Kashiwagi H, Seki T, Yasuda A, Ando K, Ito M, Tokuda Y, Kametani Y. HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice. Sci Rep 2021;11:12798. [PMID: 34140620 DOI: 10.1038/s41598-021-92311-y] [Reference Citation Analysis]
223 Caruana I, Simula L, Locatelli F, Campello S. T lymphocytes against solid malignancies: winning ways to defeat tumours. Cell Stress 2018;2:200-12. [PMID: 31225487 DOI: 10.15698/cst2018.07.148] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
224 Kawashita S, Aoyagi K, Yamanaka H, Hantani R, Naruoka S, Tanimoto A, Hori Y, Toyonaga Y, Fukushima K, Miyazaki S, Hantani Y. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction. Bioorganic & Medicinal Chemistry Letters 2019;29:2464-7. [DOI: 10.1016/j.bmcl.2019.07.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
225 Ali MHM, Toor SM, Rakib F, Mall R, Ullah E, Mroue K, Kolatkar PR, Al-Saad K, Elkord E. Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy. Vaccines (Basel) 2019;7:E109. [PMID: 31505846 DOI: 10.3390/vaccines7030109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
226 Teruya K, Kusumoto Y, Eto H, Nakamichi N, Shirahata S. Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract. Mar Drugs 2019;17:E421. [PMID: 31331053 DOI: 10.3390/md17070421] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
227 Garofalo M, Bertinato L, Staniszewska M, Wieczorek M, Salmaso S, Schrom S, Rinner B, Pancer KW, Kuryk L. Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model. Pharmaceutics 2021;13:547. [PMID: 33919827 DOI: 10.3390/pharmaceutics13040547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Kun E, Tsang YTM, Ng CW, Gershenson DM, Wong KK. MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev 2021;92:102137. [PMID: 33340965 DOI: 10.1016/j.ctrv.2020.102137] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
229 Setordzi P, Chang X, Liu Z, Wu Y, Zuo D. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. Eur J Pharmacol 2021;895:173867. [PMID: 33460617 DOI: 10.1016/j.ejphar.2021.173867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Sau S, Alsaab HO, Bhise K, Alzhrani R, Nabil G, Iyer AK. Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment. J Control Release 2018;274:24-34. [PMID: 29391232 DOI: 10.1016/j.jconrel.2018.01.028] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 26.0] [Reference Citation Analysis]
231 Sau S, Tatiparti K, Alsaab HO, Kashaw SK, Iyer AK. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy. Drug Discov Today 2018;23:1344-56. [PMID: 29551455 DOI: 10.1016/j.drudis.2018.03.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
232 Liu C, Lai H, Chen T. Boosting Natural Killer Cell-Based Cancer Immunotherapy with Selenocystine/Transforming Growth Factor-Beta Inhibitor-Encapsulated Nanoemulsion. ACS Nano 2020;14:11067-82. [PMID: 32806028 DOI: 10.1021/acsnano.9b10103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
233 Chuang YC, Tseng JC, Huang LR, Huang CM, Huang CF, Chuang TH. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. Front Immunol 2020;11:1075. [PMID: 32547560 DOI: 10.3389/fimmu.2020.01075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
234 Kobayashi G, Sentani K, Babasaki T, Sekino Y, Shigematsu Y, Hayashi T, Oue N, Teishima J, Matsubara A, Sasaki N, Yasui W. Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma. Cancer Sci 2020;111:1020-7. [PMID: 31912588 DOI: 10.1111/cas.14299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
235 Amani H, Shahbazi MA, D'Amico C, Fontana F, Abbaszadeh S, Santos HA. Microneedles for painless transdermal immunotherapeutic applications. J Control Release 2021;330:185-217. [PMID: 33340568 DOI: 10.1016/j.jconrel.2020.12.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 27.0] [Reference Citation Analysis]
236 Kouidhi S, Ben Ayed F, Benammar Elgaaied A. Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. Front Immunol 2018;9:353. [PMID: 29527212 DOI: 10.3389/fimmu.2018.00353] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 22.7] [Reference Citation Analysis]
237 Inthagard J, Edwards J, Roseweir AK. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. Clin Sci (Lond) 2019;133:181-93. [PMID: 30659159 DOI: 10.1042/CS20181003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
238 Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. Biochim Biophys Acta Rev Cancer. 2017;1868:564-570. [PMID: 29054475 DOI: 10.1016/j.bbcan.2017.10.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 18.0] [Reference Citation Analysis]
239 Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B 2021;11:941-60. [PMID: 33996408 DOI: 10.1016/j.apsb.2020.12.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
240 Drakes ML, Stiff PJ. Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment. Cancers (Basel) 2018;10:E302. [PMID: 30200478 DOI: 10.3390/cancers10090302] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 14.0] [Reference Citation Analysis]
241 Ardolino L, Joshua A. Immune checkpoint inhibitors in malignancy. Aust Prescr 2019;42:62-7. [PMID: 31048940 DOI: 10.18773/austprescr.2019.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
242 Abdin SM, Zaher DM, Arafa EA, Omar HA. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers (Basel). 2018;10. [PMID: 29370105 DOI: 10.3390/cancers10020032] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 11.3] [Reference Citation Analysis]
243 Ma Q, Long W, Xing C, Chu J, Luo M, Wang HY, Liu Q, Wang RF. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. Front Immunol 2018;9:2924. [PMID: 30619286 DOI: 10.3389/fimmu.2018.02924] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 19.0] [Reference Citation Analysis]
244 Liang JL, Luo GF, Chen WH, Zhang XZ. Recent Advances in Engineered Materials for Immunotherapy-Involved Combination Cancer Therapy. Adv Mater 2021;33:e2007630. [PMID: 34050564 DOI: 10.1002/adma.202007630] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Morand S, Stanbery L, Walter A, Rocconi RP, Nemunaitis J. BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target. JNCI Cancer Spectr 2020;4:pkaa077. [PMID: 33409454 DOI: 10.1093/jncics/pkaa077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
246 Zheng J, Huang J, Ma W, Yang W, Hu B. The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models. Cancer Manag Res 2021;13:6045-53. [PMID: 34377023 DOI: 10.2147/CMAR.S321402] [Reference Citation Analysis]
247 Wołącewicz M, Hrynkiewicz R, Grywalska E, Suchojad T, Leksowski T, Roliński J, Niedźwiedzka-Rystwej P. Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. Cancers (Basel) 2020;12:E1181. [PMID: 32392774 DOI: 10.3390/cancers12051181] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 24.0] [Reference Citation Analysis]
248 Duan X, Chan C, Han W, Guo N, Weichselbaum RR, Lin W. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat Commun 2019;10:1899. [PMID: 31015397 DOI: 10.1038/s41467-019-09221-x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 69] [Article Influence: 43.5] [Reference Citation Analysis]
249 Rahman W, Conley A, Silver KD. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma. BMJ Case Rep 2020;13:e233842. [PMID: 32616532 DOI: 10.1136/bcr-2019-233842] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Marshall HT, Djamgoz MBA. Immuno-Oncology: Emerging Targets and Combination Therapies. Front Oncol. 2018;8:315. [PMID: 30191140 DOI: 10.3389/fonc.2018.00315] [Cited by in Crossref: 134] [Cited by in F6Publishing: 112] [Article Influence: 44.7] [Reference Citation Analysis]
251 Vrána D, Matzenauer M, Neoral Č, Aujeský R, Vrba R, Melichar B, Rušarová N, Bartoušková M, Jankowski J. From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer. Int J Mol Sci 2018;20:E13. [PMID: 30577521 DOI: 10.3390/ijms20010013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 13.3] [Reference Citation Analysis]
252 Yu WQ, Ji NF, Gu CJ, Sun ZX, Wang ZX, Chen ZQ, Ma Y, Wu ZZ, Wang YL, Wu CJ, Ding MD, Dai GH, Yao J, Jin RR, Huang M, Zhang MS. Downregulation of miR-4772-3p promotes enhanced regulatory T cell capacity in malignant pleural effusion by elevating Helios levels. Chin Med J (Engl) 2019;132:2705-15. [PMID: 31725455 DOI: 10.1097/CM9.0000000000000517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
253 Mcgowan E, Lin Q, Ma G, Yin H, Chen S, Lin Y. PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomedicine & Pharmacotherapy 2020;121:109625. [DOI: 10.1016/j.biopha.2019.109625] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 27.0] [Reference Citation Analysis]
254 Wang X, Wu M, Cao Y, Zhang Z, Guo F, Li X, Zhang Y. Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases. Crit Rev Clin Lab Sci 2019;56:18-32. [PMID: 30602320 DOI: 10.1080/10408363.2018.1522292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol 2020;13:45. [PMID: 32370812 DOI: 10.1186/s13045-020-00876-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
256 Ayala-Mar S, Donoso-Quezada J, González-Valdez J. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy. J Immunol Res 2021;2021:8839978. [PMID: 33628854 DOI: 10.1155/2021/8839978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
257 Isakov N. Cancer immunotherapy by targeting immune checkpoint receptors. WJI 2018;8:1-11. [DOI: 10.5411/wji.v8.i1.1] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
258 Warren JSA, Xiao Y, Lamar JM. YAP/TAZ Activation as a Target for Treating Metastatic Cancer. Cancers (Basel) 2018;10:E115. [PMID: 29642615 DOI: 10.3390/cancers10040115] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 24.0] [Reference Citation Analysis]
259 Rezazadeh H, Astaneh M, Tehrani M, Hossein-Nataj H, Zaboli E, Shekarriz R, Asgarian-Omran H. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8+ T cells in early clinical stages of chronic lymphocytic leukemia. Immunol Res 2020;68:269-79. [PMID: 32710227 DOI: 10.1007/s12026-020-09146-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
260 Chüeh AC, Liew MS, Russell PA, Walkiewicz M, Jayachandran A, Starmans MHW, Boutros PC, Wright G, Barnett SA, Mariadason JM, John T. Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. Oncotarget 2017;8:74036-48. [PMID: 29088766 DOI: 10.18632/oncotarget.18198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
261 George JT, Levine H. Stochastic modeling of tumor progression and immune evasion. J Theor Biol 2018;458:148-55. [PMID: 30218648 DOI: 10.1016/j.jtbi.2018.09.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
262 Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol 2020;83:1239-53. [PMID: 32461079 DOI: 10.1016/j.jaad.2020.03.131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
263 Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol 2018;25:342-7. [PMID: 30464684 DOI: 10.3747/co.25.4235] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 19.3] [Reference Citation Analysis]
264 Silvestris N, Brunetti O, Pinto R, Petriella D, Argentiero A, Fucci L, Tommasi S, Danza K, De Summa S. Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. Expert Opin Ther Targets 2018;22:453-61. [PMID: 29561217 DOI: 10.1080/14728222.2018.1456530] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
265 Liu X, Wu F, Ji Y, Yin L. Recent Advances in Anti-cancer Protein/Peptide Delivery. Bioconjugate Chem 2019;30:305-24. [DOI: 10.1021/acs.bioconjchem.8b00750] [Cited by in Crossref: 52] [Cited by in F6Publishing: 32] [Article Influence: 17.3] [Reference Citation Analysis]
266 Iranzo I, Huguet JM, Suárez P, Ferrer-Barceló L, Iranzo V, Sempere J. Endoscopic evaluation of immunotherapy-induced gastrointestinal toxicity. World J Gastrointest Endosc 2018;10:392-9. [PMID: 30631403 DOI: 10.4253/wjge.v10.i12.392] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
267 Shokati A, Naser Moghadasi A, Nikbakht M, Sahraian MA, Mousavi SA, Ai J. A focus on allogeneic mesenchymal stromal cells as a versatile therapeutic tool for treating multiple sclerosis. Stem Cell Res Ther 2021;12:400. [PMID: 34256857 DOI: 10.1186/s13287-021-02477-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Barros LRC, Paixão EA, Valli AMP, Naozuka GT, Fassoni AC, Almeida RC. CARTmath-A Mathematical Model of CAR-T Immunotherapy in Preclinical Studies of Hematological Cancers. Cancers (Basel) 2021;13:2941. [PMID: 34208323 DOI: 10.3390/cancers13122941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Fanelli G, Romano M, Nova-Lamperti E, Werner Sunderland M, Nerviani A, Scottà C, Bombardieri M, Quezada SA, Sacks SH, Noelle RJ, Pitzalis C, Lechler RI, Lombardi G, Becker PD. PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype. PLoS Biol 2021;19:e3001199. [PMID: 33901179 DOI: 10.1371/journal.pbio.3001199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
270 Doronin AN, Gordeev AA, Kozlov AE, Smirnova YA, Puchkova MY, Ekimova VM, Basovskiy YI, Solovyev VV. T-Cell Engagers Based Bioassay for Evaluation of PD-1/PD-L1 Inhibitors Activity. Biochemistry (Mosc) 2019;84:711-9. [PMID: 31509723 DOI: 10.1134/S0006297919070034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
271 Biteghe FAN, Chalomie NET, Mungra N, Vignaux G, Gao N, Vergeade A, Okem A, Naran K, Ndong JC, Barth S. Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma. Biomedicines 2020;8:E327. [PMID: 32899183 DOI: 10.3390/biomedicines8090327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
272 Guo D, Ji X, Luo J. Rational nanocarrier design towards clinical translation of cancer nanotherapy. Biomed Mater 2021;16:032005. [DOI: 10.1088/1748-605x/abe35a] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
273 Saab S, Zalzale H, Rahal Z, Khalifeh Y, Sinjab A, Kadara H. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Front Immunol 2020;11:159. [PMID: 32117295 DOI: 10.3389/fimmu.2020.00159] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
274 Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19:1338-1350. [PMID: 30213452 DOI: 10.1016/s1470-2045(18)30495-9] [Cited by in Crossref: 133] [Cited by in F6Publishing: 64] [Article Influence: 44.3] [Reference Citation Analysis]
275 Jing X, Shao S, Zhang Y, Luo A, Zhao L, Zhang L, Gu S, Zhao X. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer. Exp Cell Res 2020;392:112034. [PMID: 32339606 DOI: 10.1016/j.yexcr.2020.112034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
276 Alcantar D, Al-Jaashaami L, Giron F. A Case of Immune Checkpoint Inhibitor Refractory Colitis Treated with Mycophenolate and High-dose Steroids. Cureus 2019;11:e6392. [PMID: 31938669 DOI: 10.7759/cureus.6392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
277 Hacking S, Vitkovski T, Jain S, Jin C, Chavarria H, Wu D, Nasim M. Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma. Appl Immunohistochem Mol Morphol 2021;29:201-8. [PMID: 32842025 DOI: 10.1097/PAI.0000000000000868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Nikolaev EV, Zloza A, Sontag ED. Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions. Front Immunol 2019;10:4. [PMID: 30745900 DOI: 10.3389/fimmu.2019.00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
279 Chen Y, Pei Y, Luo J, Huang Z, Yu J, Meng X. Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. Front Immunol 2020;11:1088. [PMID: 32547566 DOI: 10.3389/fimmu.2020.01088] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
280 Leslie I, Boos LA, Larkin J, Pickering L. Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. Expert Rev Anticancer Ther 2020;20:343-54. [PMID: 32293937 DOI: 10.1080/14737140.2020.1756780] [Reference Citation Analysis]
281 Broos K, Lecocq Q, Raes G, Devoogdt N, Keyaerts M, Breckpot K. Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics 2018;8:3559-70. [PMID: 30026866 DOI: 10.7150/thno.24762] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 15.7] [Reference Citation Analysis]
282 Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer Therapy-Associated Thrombosis. Arterioscler Thromb Vasc Biol 2021;41:1291-305. [PMID: 33567864 DOI: 10.1161/ATVBAHA.120.314378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
283 Xu Y, Xiao Y, Luo C, Liu Q, Wei A, Yang Y, Zhao L, Wang Y. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. Int Immunopharmacol 2020;84:106584. [PMID: 32422527 DOI: 10.1016/j.intimp.2020.106584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
284 Basu S, Yang J, Xu B, Magiera-Mularz K, Skalniak L, Musielak B, Kholodovych V, Holak TA, Hu L. Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. J Med Chem 2019;62:7250-63. [PMID: 31298541 DOI: 10.1021/acs.jmedchem.9b00795] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
285 Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha BL, Duewell P, Endres S, Kobold S. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. Front Immunol 2018;9:1955. [PMID: 30214445 DOI: 10.3389/fimmu.2018.01955] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
286 Rocco D, Gravara LD, Gridelli C. The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives. Curr Clin Pharmacol 2020;15:11-9. [PMID: 31400270 DOI: 10.2174/1574884714666190809124555] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
287 Blair HA. Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer. Target Oncol 2018;13:399-407. [PMID: 29785577 DOI: 10.1007/s11523-018-0570-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
288 Liang X, Guan Y, Zhang B, Liang J, Wang B, Li Y, Wang J. Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature. Front Oncol 2019;9:1437. [PMID: 31921686 DOI: 10.3389/fonc.2019.01437] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
289 Bashir B, Wilson MA. Novel Immunotherapy Combinations. Curr Oncol Rep 2019;21:96. [PMID: 31696332 DOI: 10.1007/s11912-019-0851-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
290 Kim KS, Kim DH, Kim DH. Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles. Pharmaceutics 2021;13:525. [PMID: 33918941 DOI: 10.3390/pharmaceutics13040525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Mokhtari RB, Sambi M, Qorri B, Baluch N, Ashayeri N, Kumar S, Cheng HM, Yeger H, Das B, Szewczuk MR. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers (Basel) 2021;13:3596. [PMID: 34298809 DOI: 10.3390/cancers13143596] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
292 Chen MC, Pangilinan CR, Lee CH. Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression. Cancers (Basel) 2019;12:E57. [PMID: 31878272 DOI: 10.3390/cancers12010057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
293 Łasińska I, Kolenda T, Teresiak A, Lamperska KM, Galus Ł, Mackiewicz J. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. Anticancer Agents Med Chem 2019;19:290-303. [PMID: 30198439 DOI: 10.2174/1871520618666180910092356] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
294 Su C, Wang H, Liu Y, Guo Q, Zhang L, Li J, Zhou W, Yan Y, Zhou X, Zhang J. Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. Front Oncol 2020;10:554313. [PMID: 33072580 DOI: 10.3389/fonc.2020.554313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
295 Manukian G, Bar-Ad V, Lu B, Argiris A, Johnson JM. Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. Front Oncol 2019;9:122. [PMID: 30895168 DOI: 10.3389/fonc.2019.00122] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
296 Menyhárt O, Pongor LS, Győrffy B. Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer. Front Pharmacol 2018;9:1522. [PMID: 30670970 DOI: 10.3389/fphar.2018.01522] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
297 Bhise K, Sau S, Alsaab H, Kashaw SK, Tekade RK, Iyer AK. Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship. Ther Deliv 2017;8:1003-18. [PMID: 29061101 DOI: 10.4155/tde-2017-0062] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 11.3] [Reference Citation Analysis]
298 Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, Hajiasgharzadeh K, Baghbanzadeh A, Safarpour H, Mokhtarzadeh A, Brunetti O, Yue SC, Silvestris N, Baradaran B. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies? Int J Mol Sci 2020;21:E8305. [PMID: 33167514 DOI: 10.3390/ijms21218305] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 17.0] [Reference Citation Analysis]
299 Makuku R, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. J Immunol Res 2021;2021:6661406. [PMID: 33681388 DOI: 10.1155/2021/6661406] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
300 Lan Q, Xia S, Wang Q, Xu W, Huang H, Jiang S, Lu L. Development of oncolytic virotherapy: from genetic modification to combination therapy. Front Med 2020;14:160-84. [PMID: 32146606 DOI: 10.1007/s11684-020-0750-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
301 Bastaki S, Aravindhan S, Ahmadpour Saheb N, Afsari Kashani M, Evgenievich Dorofeev A, Karoon Kiani F, Jahandideh H, Beigi Dargani F, Aksoun M, Nikkhoo A, Masjedi A, Mahmoodpoor A, Ahmadi M, Dolati S, Namvar Aghdash S, Jadidi-Niaragh F. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice. Life Sci 2021;266:118847. [PMID: 33309720 DOI: 10.1016/j.lfs.2020.118847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
302 Bueno MJ, Ruiz-Sepulveda JL, Quintela-Fandino M. Mitochondrial Inhibition: a Treatment Strategy in Cancer? Curr Oncol Rep 2021;23:49. [PMID: 33730242 DOI: 10.1007/s11912-021-01033-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Miller AL, Garcia PL, Yoon KJ. Developing effective combination therapy for pancreatic cancer: An overview. Pharmacol Res 2020;155:104740. [PMID: 32135247 DOI: 10.1016/j.phrs.2020.104740] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
304 Khoshghamat N, Jafari N, Moetamani-Ahmadi M, Khalili-Tanha G, Khajavi Rad MH, Sahebdel S, Khalili-Tanha N, Soleimanpour S, Khazaei M, Hassanian SM, Ferns GA, Avan A. Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers. Pathol Res Pract 2021;220:153390. [PMID: 33640713 DOI: 10.1016/j.prp.2021.153390] [Reference Citation Analysis]
305 Hemminki O, Oksanen M, Taipale K, Liikanen I, Koski A, Joensuu T, Kanerva A, Hemminki A. Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy. Mol Ther Oncolytics 2018;9:41-50. [PMID: 29989063 DOI: 10.1016/j.omto.2018.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
306 Shah R, Chen S. Metabolic Signaling Cascades Prompted by Glutaminolysis in Cancer. Cancers (Basel) 2020;12:E2624. [PMID: 32937954 DOI: 10.3390/cancers12092624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
307 Ahmed N, Kadife E, Raza A, Short M, Jubinsky PT, Kannourakis G. Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells 2020;9:E719. [PMID: 32183385 DOI: 10.3390/cells9030719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
308 Yang L, Dong XZ, Xing XX, Cui XH, Li L, Zhang L. Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis. World J Gastrointest Oncol 2020;12:1346-63. [PMID: 33250966 DOI: 10.4251/wjgo.v12.i11.1346] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
309 Gao Y, Chen L, Cai G, Xiong X, Wu Y, Ma D, Li SC, Gao Q. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study. Oncoimmunology 2020;9:1760067. [PMID: 32391193 DOI: 10.1080/2162402X.2020.1760067] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
310 Mylvaganam GH, Chea LS, Tharp GK, Hicks S, Velu V, Iyer SS, Deleage C, Estes JD, Bosinger SE, Freeman GJ, Ahmed R, Amara RR. Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. JCI Insight 2018;3:122940. [PMID: 30232277 DOI: 10.1172/jci.insight.122940] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 15.0] [Reference Citation Analysis]
311 Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, Deshmukh RR. Immunotherapies and Combination Strategies for Immuno-Oncology. Int J Mol Sci 2020;21:E5009. [PMID: 32679922 DOI: 10.3390/ijms21145009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
312 Zabel M, Tauber PA, Pickl WF. The making and function of CAR cells. Immunol Lett 2019;212:53-69. [PMID: 31181279 DOI: 10.1016/j.imlet.2019.06.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
313 Liu HC, Viswanath DI, Pesaresi F, Xu Y, Zhang L, Di Trani N, Paez-Mayorga J, Hernandez N, Wang Y, Erm DR, Ho J, Susnjar A, Liu X, Demaria S, Chen SH, Teh BS, Butler EB, Xuan Chua CY, Grattoni A. Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1. Int J Radiat Oncol Biol Phys 2021;110:492-506. [PMID: 32768562 DOI: 10.1016/j.ijrobp.2020.07.2326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
314 Huang X, Xu J, Wu Y, Sheng L, Li Y, Zha B, Sun T, Yang J, Zang S, Liu J. Alterations in CD8+ Tregs, CD56+ Natural Killer Cells and IL-10 Are Associated With Invasiveness of Nonfunctioning Pituitary Adenomas (NFPAs). Pathol Oncol Res 2021;27:598887. [PMID: 34257554 DOI: 10.3389/pore.2021.598887] [Reference Citation Analysis]
315 Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. Front Oncol. 2018;8:386. [PMID: 30283733 DOI: 10.3389/fonc.2018.00386] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 25.7] [Reference Citation Analysis]
316 Zhou K, Guo S, Li F, Sun Q, Liang G. Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. Front Cell Dev Biol 2020;8:569219. [PMID: 33178688 DOI: 10.3389/fcell.2020.569219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
317 Huang LJ, Deng XF, Chang F, Wu XL, Wu Y, Diao QZ. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12858. [PMID: 30412078 DOI: 10.1097/MD.0000000000012858] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
318 Gong F, Ma JC, Jia J, Li FZ, Wu JL, Wang S, Teng X, Cui ZK. Synergistic effect of the anti-PD-1 antibody with blood stable and reduction sensitive curcumin micelles on colon cancer. Drug Deliv 2021;28:930-42. [PMID: 33975498 DOI: 10.1080/10717544.2021.1921077] [Reference Citation Analysis]
319 Cui J, Li Q, Luo M, Zhong Z, Zhou S, Jiang L, Shen N, Geng Z, Cheng H, Meng L, Yi S, Sun H, Wu F, Zhu Z, Zou P, You Y, Guo AY, Zhu X. Leukemia cell-derived microvesicles induce T cell exhaustion via miRNA delivery. Oncoimmunology 2018;7:e1448330. [PMID: 29900066 DOI: 10.1080/2162402X.2018.1448330] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
320 Weng CY, Kao CX, Chang TS, Huang YH. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance. Int J Mol Sci 2021;22:1258. [PMID: 33514004 DOI: 10.3390/ijms22031258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Alomar M, Fradley MG. Electrophysiology Translational Considerations in Cardio-Oncology: QT and Beyond. J of Cardiovasc Trans Res 2020;13:390-401. [DOI: 10.1007/s12265-019-09924-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
322 Tsonis O, Karpathiou G, Tsonis K, Paschopoulos M, Papoudou-Bai A, Kanavaros P. Immune cells in normal pregnancy and gestational trophoblastic diseases. Placenta 2020;101:90-6. [PMID: 32942146 DOI: 10.1016/j.placenta.2020.09.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Anugwom C, Leventhal T. Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient. ACG Case Rep J 2020;7:e00416. [PMID: 32766358 DOI: 10.14309/crj.0000000000000416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
324 Balibegloo M, Nejadghaderi SA, Sadeghalvad M, Soleymanitabar A, Salehi Nezamabadi S, Saghazadeh A, Rezaei N. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. Int Immunopharmacol 2021;96:107796. [PMID: 34162158 DOI: 10.1016/j.intimp.2021.107796] [Reference Citation Analysis]
325 Iscaro A, Howard NF, Muthana M. Nanoparticles: Properties and Applications in Cancer Immunotherapy. Curr Pharm Des 2019;25:1962-79. [PMID: 31566122 DOI: 10.2174/1381612825666190708214240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
326 Zhang N, Tu J, Wang X, Chu Q. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy 2019;11:429-41. [PMID: 30698054 DOI: 10.2217/imt-2018-0110] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
327 Roderburg C, Berres ML, Wree A, Loosen SH, Luedde T, Trautwein C. Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visc Med 2019;35:43-6. [PMID: 31312649 DOI: 10.1159/000497465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
328 Kopalli SR, Kang T, Lee K, Koppula S. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. PRA 2019;14:100-12. [DOI: 10.2174/1574892813666181029142812] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
329 Finlay WJJ, Coleman JE, Edwards JS, Johnson KS. Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement. MAbs. 2019;11:26-44. [PMID: 30541416 DOI: 10.1080/19420862.2018.1550321] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
330 Wiraja C, Mori Y, Ichimura T, Hwang J, Xu C, Bonventre JV. Nephrotoxicity Assessment with Human Kidney Tubuloids using Spherical Nucleic Acid-Based mRNA Nanoflares. Nano Lett 2021;21:5850-8. [PMID: 34156251 DOI: 10.1021/acs.nanolett.1c01840] [Reference Citation Analysis]
331 Allouch S, Malki A, Allouch A, Gupta I, Vranic S, Al Moustafa AE. High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions. Front Oncol 2020;10:914. [PMID: 32695664 DOI: 10.3389/fonc.2020.00914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
332 Alsaab HO, Al-Hibs AS, Alzhrani R, Alrabighi KK, Alqathama A, Alwithenani A, Almalki AH, Althobaiti YS. Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine. Int J Mol Sci 2021;22:1631. [PMID: 33562829 DOI: 10.3390/ijms22041631] [Reference Citation Analysis]
333 Gao H, Wu Y, Shi J, Zhang X, Liu T, Hu B, Jia B, Wan Y, Liu Z, Wang F. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. J Immunother Cancer 2020;8:e001156. [PMID: 33203663 DOI: 10.1136/jitc-2020-001156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
334 Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 2019;572:392-6. [PMID: 31367043 DOI: 10.1038/s41586-019-1456-0] [Cited by in Crossref: 225] [Cited by in F6Publishing: 189] [Article Influence: 112.5] [Reference Citation Analysis]
335 Rizzo A, Dadduzio V, Ricci AD, Massari F, Di Federico A, Gadaleta-Caldarola G, Brandi G. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs 2021;:1-8. [PMID: 34167433 DOI: 10.1080/13543784.2021.1948532] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
336 Song Q, Zhang G, Wang B, Cao G, Li D, Wang Y, Zhang Y, Geng J, Li H, Li Y. Reinforcing the Combinational Immuno-Oncotherapy of Switching "Cold" Tumor to "Hot" by Responsive Penetrating Nanogels. ACS Appl Mater Interfaces 2021;13:36824-38. [PMID: 34314148 DOI: 10.1021/acsami.1c08201] [Reference Citation Analysis]
337 Hoeres T, Smetak M, Pretscher D, Wilhelm M. Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer. Front Immunol 2018;9:800. [PMID: 29725332 DOI: 10.3389/fimmu.2018.00800] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 18.0] [Reference Citation Analysis]
338 Koelzer VH, Gisler A, Hanhart JC, Griss J, Wagner SN, Willi N, Cathomas G, Sachs M, Kempf W, Thommen DS, Mertz KD. Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma. Histopathology 2018;73:397-406. [PMID: 29660160 DOI: 10.1111/his.13528] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
339 Yang JH, Kim H, Roh SY, Lee MA, Park JM, Lee HH, Park CH, Lee HH, Jung ES, Lee SH, Lee YJ, Choi MH, Kim O, Kim IH. Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer. Gastric Cancer 2019;22:147-54. [PMID: 29860599 DOI: 10.1007/s10120-018-0842-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
340 Bonamichi-Santos R, Aun MV, Kalil J, Castells MC, Giavina-Bianchi P. PD-L1 Blockade During Allergen Sensitization Inhibits the Synthesis of Specific Antibodies and Decreases Mast Cell Activation in a Murine Model of Active Cutaneous Anaphylaxis. Front Immunol 2021;12:655958. [PMID: 33968057 DOI: 10.3389/fimmu.2021.655958] [Reference Citation Analysis]
341 Sadasivam M, Noel S, Lee SA, Gong J, Allaf ME, Pierorazio P, Rabb H, Hamad ARA. Activation and Proliferation of PD-1+ Kidney Double-Negative T Cells Is Dependent on Nonclassical MHC Proteins and IL-2. J Am Soc Nephrol 2019;30:277-92. [PMID: 30622155 DOI: 10.1681/ASN.2018080815] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
342 Ren D, Zhao J, Sun Y, Li D, Meng Z, Wang B, Fan P, Liu Z, Jin X, Wu H. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway. J Exp Clin Cancer Res 2019;38:485. [PMID: 31818309 DOI: 10.1186/s13046-019-1496-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
343 Insel PA, Sriram K, Wiley SZ, Wilderman A, Katakia T, McCann T, Yokouchi H, Zhang L, Corriden R, Liu D, Feigin ME, French RP, Lowy AM, Murray F. GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets. Front Pharmacol 2018;9:431. [PMID: 29872392 DOI: 10.3389/fphar.2018.00431] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 18.0] [Reference Citation Analysis]
344 Ding Y, Liu N, Chen M, Xu Y, Fang S, Xiang W, Hua X, Chen G, Zhong Y, Yu H. Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA. World J Surg Oncol 2021;19:133. [PMID: 33888142 DOI: 10.1186/s12957-021-02231-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
345 Ma L, Gai J, Qiao P, Li Y, Li X, Zhu M, Li G, Wan Y. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade. Biochemical and Biophysical Research Communications 2020;531:144-51. [DOI: 10.1016/j.bbrc.2020.07.072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
346 Bruns HA, Deaver J, Justement LB. Out of the Curricular Shadows: Revolutionizing Undergraduate Immunology Education. Front Immunol 2019;10:2446. [PMID: 31681323 DOI: 10.3389/fimmu.2019.02446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
347 Raimondo S, Pucci M, Alessandro R, Fontana S. Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. Int J Mol Sci 2020;21:E2286. [PMID: 32225076 DOI: 10.3390/ijms21072286] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
348 Ishihara J, Ishihara A, Sasaki K, Lee SS, Williford JM, Yasui M, Abe H, Potin L, Hosseinchi P, Fukunaga K, Raczy MM, Gray LT, Mansurov A, Katsumata K, Fukayama M, Kron SJ, Swartz MA, Hubbell JA. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med 2019;11:eaau3259. [PMID: 30971453 DOI: 10.1126/scitranslmed.aau3259] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 61.0] [Reference Citation Analysis]
349 Comito G, Iscaro A, Bacci M, Morandi A, Ippolito L, Parri M, Montagnani I, Raspollini MR, Serni S, Simeoni L, Giannoni E, Chiarugi P. Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis. Oncogene 2019;38:3681-95. [PMID: 30664688 DOI: 10.1038/s41388-019-0688-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 26.0] [Reference Citation Analysis]
350 Liang J, Chen D, Chen L, She X, Zhang H, Xiao Y. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers. Future Oncol 2020;16:1211-23. [PMID: 32396026 DOI: 10.2217/fon-2020-0118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
351 Abdou P, Wang Z, Chen Q, Chan A, Zhou DR, Gunadhi V, Gu Z. Advances in engineering local drug delivery systems for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2020;12:e1632. [PMID: 32255276 DOI: 10.1002/wnan.1632] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
352 Rustum YM, Chintala S, Durrani FA, Bhattacharya A. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy. Int J Mol Sci 2018;19:E3378. [PMID: 30380599 DOI: 10.3390/ijms19113378] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
353 Chan LL, Chan SL. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2021;26:39-52. [PMID: 33724135 DOI: 10.1080/14728214.2021.1902503] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
354 Ağaçkıran Y, Aksu F, Akyürek N, Ercan C, Demiröz M, Aksu K. Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma. Asia Pac J Clin Oncol 2021;17:280-8. [PMID: 32929886 DOI: 10.1111/ajco.13460] [Reference Citation Analysis]
355 Tian CY, Ou YH, Chang SL, Lin CM. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. J Med Case Rep 2021;15:244. [PMID: 33926558 DOI: 10.1186/s13256-021-02722-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
356 Leuci V, Donini C, Grignani G, Rotolo R, Mesiano G, Fiorino E, Gammaitoni L, D'Ambrosio L, Merlini A, Landoni E, Medico E, Capellero S, Giraudo L, Cattaneo G, Iaia I, Pignochino Y, Basiricò M, Vigna E, Pisacane A, Fagioli F, Ferrone S, Aglietta M, Dotti G, Sangiolo D. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. Clin Cancer Res 2020;26:6321-34. [PMID: 32900797 DOI: 10.1158/1078-0432.CCR-20-0357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
357 Anampa J, Sparano JA. New agents for the management of resistant metastatic breast cancer. Expert Opinion on Pharmacotherapy 2017;18:1815-31. [DOI: 10.1080/14656566.2017.1409206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
358 Patel H, Yacoub N, Mishra R, White A, Long Y, Alanazi S, Garrett JT. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers (Basel) 2020;12:E482. [PMID: 32092958 DOI: 10.3390/cancers12020482] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 33.0] [Reference Citation Analysis]
359 Gong Y, Chen M, Tan Y, Shen J, Jin Q, Deng W, Sun J, Wang C, Liu Z, Chen Q. Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy. ACS Appl Mater Interfaces 2020;12:50248-59. [PMID: 33135879 DOI: 10.1021/acsami.0c13943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
360 Nabil G, Bhise K, Sau S, Atef M, El-Banna HA, Iyer AK. Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation. Drug Discov Today 2019;24:462-91. [PMID: 30121330 DOI: 10.1016/j.drudis.2018.08.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
361 Xu J, Wang H, Xu L, Chao Y, Wang C, Han X, Dong Z, Chang H, Peng R, Cheng Y, Liu Z. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy. Biomaterials 2019;207:1-9. [PMID: 30947117 DOI: 10.1016/j.biomaterials.2019.03.037] [Cited by in Crossref: 58] [Cited by in F6Publishing: 40] [Article Influence: 29.0] [Reference Citation Analysis]
362 Wu J, Chen J, Feng Y, Zhang S, Lin L, Guo Z, Sun P, Xu C, Tian H, Chen X. An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles. Sci Adv 2020;6:eabc7828. [PMID: 32998884 DOI: 10.1126/sciadv.abc7828] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 17.0] [Reference Citation Analysis]
363 Freitas MA, Vasconcelos A, Gonçalves ECD, Ferrarini EG, Vieira GB, Cicia D, Cola M, Capasso R, Dutra RC. Involvement of Opioid System and TRPM8/TRPA1 Channels in the Antinociceptive Effect of Spirulina platensis. Biomolecules 2021;11:592. [PMID: 33920609 DOI: 10.3390/biom11040592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Sanaei M, Pourbagheri-sigaroodi A, Kaveh V, Sheikholeslami SA, Salari S, Bashash D. The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology 2021;157:103160. [DOI: 10.1016/j.critrevonc.2020.103160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
365 Liu H, Zhao Z, Zhang L, Li Y, Jain A, Barve A, Jin W, Liu Y, Fetse J, Cheng K. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. J Immunother Cancer 2019;7:270. [PMID: 31640814 DOI: 10.1186/s40425-019-0705-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
366 Wang Z, Sau S, Alsaab HO, Iyer AK. CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 2018;14:1441-54. [PMID: 29678787 DOI: 10.1016/j.nano.2018.04.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
367 Wei XL, Ren C, Wang FH, Zhang Y, Zhao HY, Zou BY, Wang ZQ, Qiu MZ, Zhang DS, Luo HY, Wang F, Yao S, Xu RH. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. Cancer Commun (Lond) 2020;40:345-54. [PMID: 32589350 DOI: 10.1002/cac2.12068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
368 Zhao Y, Jia Y, Shi T, Wang W, Shao D, Zheng X, Sun M, He K, Chen L. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis 2019. [PMID: 30715244 DOI: 10.1093/carcin/bgz017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
369 Tian S, Switchenko JM, Buchwald ZS, Patel PR, Shelton JW, Kahn SE, Pillai RN, Steuer CE, Owonikoko TK, Behera M, Curran WJ, Higgins KA. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108:304-313. [PMID: 31982496 DOI: 10.1016/j.ijrobp.2019.12.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
370 Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS. Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opin Ther Targets 2018;22:9-17. [PMID: 29207896 DOI: 10.1080/14728222.2018.1413091] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
371 Petrova V, Arkhypov I, Weber R, Groth C, Altevogt P, Utikal J, Umansky V. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. Int J Mol Sci 2020;21:E2367. [PMID: 32235439 DOI: 10.3390/ijms21072367] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
372 Contursi A, Grande R, Dovizio M, Bruno A, Fullone R, Patrignani P. Platelets in cancer development and diagnosis. Biochem Soc Trans 2018;46:1517-27. [PMID: 30420412 DOI: 10.1042/BST20180159] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
373 Yuan CS, Deng ZW, Qin D, Mu YZ, Chen XG, Liu Y. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand? Acta Biomater 2021;125:1-28. [PMID: 33639310 DOI: 10.1016/j.actbio.2021.02.030] [Reference Citation Analysis]
374 Chen K, Li Y, Guo Z, Zeng Y, Zhang W, Wang H. Metformin: current clinical applications in nondiabetic patients with cancer. Aging (Albany NY) 2020;12:3993-4009. [PMID: 32074084 DOI: 10.18632/aging.102787] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
375 Gritsenko K, Lubrano M. Chemotherapy. In: Gulati A, Puttanniah V, Bruel BM, Rosenberg WS, Hung JC, editors. Essentials of Interventional Cancer Pain Management. Cham: Springer International Publishing; 2019. pp. 19-27. [DOI: 10.1007/978-3-319-99684-4_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
376 Sheng QJ, Tian WY, Dou XG, Zhang C, Li YW, Han C, Fan YX, Lai PP, Ding Y. Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma. World J Gastrointest Oncol 2020;12:1255-71. [PMID: 33250959 DOI: 10.4251/wjgo.v12.i11.1255] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
377 Bouferraa Y, Chedid A, Amhaz G, El Lakkiss A, Mukherji D, Temraz S, Shamseddine A. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. Int J Mol Sci 2021;22:8036. [PMID: 34360802 DOI: 10.3390/ijms22158036] [Reference Citation Analysis]
378 Maleknia M, Valizadeh A, Pezeshki SMS, Saki N. Immunomodulation in leukemia: cellular aspects of anti-leukemic properties. Clin Transl Oncol 2020;22:1-10. [DOI: 10.1007/s12094-019-02132-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
379 Rundo F, Bersanelli M, Urzia V, Friedlaender A, Cantale O, Calcara G, Addeo A, Banna GL. Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy. Clin Genitourin Cancer 2021:S1558-7673(21)00075-6. [PMID: 33849811 DOI: 10.1016/j.clgc.2021.03.012] [Reference Citation Analysis]
380 Manjunath M, Choudhary B. Triple-negative breast cancer: A run-through of features, classification and current therapies. Oncol Lett 2021;22:512. [PMID: 33986872 DOI: 10.3892/ol.2021.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
381 Ullrich CI, Aloni R, Saeed MEM, Ullrich W, Efferth T. Comparison between tumors in plants and human beings: Mechanisms of tumor development and therapy with secondary plant metabolites. Phytomedicine 2019;64:153081. [PMID: 31568956 DOI: 10.1016/j.phymed.2019.153081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
382 Hashemzadeh N, Dolatkhah M, Adibkia K, Aghanejad A, Barzegar-Jalali M, Omidi Y, Barar J. Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines. Life Sci 2021;271:119110. [PMID: 33513401 DOI: 10.1016/j.lfs.2021.119110] [Reference Citation Analysis]
383 Vivarelli S, Falzone L, Leonardi GC, Salmeri M, Libra M. Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). Int J Oncol 2021;59:75. [PMID: 34396439 DOI: 10.3892/ijo.2021.5255] [Reference Citation Analysis]
384 Ullah M, Aoudjeghout W, Pimpie C, Pocard M, Mirshahi M. Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1. Cancers (Basel) 2020;12:E2661. [PMID: 32961872 DOI: 10.3390/cancers12092661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
385 Zeng L, Cao Y, He L, Ding S, Bian XW, Tian G. Metal-ligand coordination nanomaterials for radiotherapy: emerging synergistic cancer therapy. J Mater Chem B 2021;9:208-27. [PMID: 33215626 DOI: 10.1039/d0tb02294b] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
386 Müller OJ, Spehlmann ME, Frey N. Cardio-toxicity of checkpoint inhibitors. J Thorac Dis 2018;10:S4400-4. [PMID: 30701107 DOI: 10.21037/jtd.2018.12.78] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
387 Wang Q, Niu D, Shi J, Wang L. A Three-in-one ZIFs-Derived CuCo(O)/GOx@PCNs Hybrid Cascade Nanozyme for Immunotherapy/Enhanced Starvation/Photothermal Therapy. ACS Appl Mater Interfaces 2021;13:11683-95. [PMID: 33656325 DOI: 10.1021/acsami.1c01006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
388 Billon E, Finetti P, Bertucci A, Niccoli P, Birnbaum D, Mamessier E, Bertucci F. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. Oncoimmunology 2019;8:e1655362. [PMID: 31646101 DOI: 10.1080/2162402X.2019.1655362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
389 Wang F, Ye W, Wang S, He Y, Zhong H, Wang Y, Zhu Y, Han J, Bing Z, Ji S, Liu H, Yao X. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia 2021;23:281-93. [PMID: 33529880 DOI: 10.1016/j.neo.2021.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
390 Mann EK, Lee KJ, Chen D, da Silva LM, Dal Zotto VL, Scalici J, Gassman NR. Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response. Biology (Basel) 2021;10:385. [PMID: 33946684 DOI: 10.3390/biology10050385] [Reference Citation Analysis]
391 Yang J, Jia Y, Wang B, Yang S, Du K, Luo Y, Li Y, Zhu B. Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1. Front Oncol 2021;11:595609. [PMID: 33777742 DOI: 10.3389/fonc.2021.595609] [Reference Citation Analysis]
392 Khosravi N, Mokhtarzadeh A, Baghbanzadeh A, Hajiasgharzadeh K, Shahgoli VK, Hemmat N, Safarzadeh E, Baradaran B. Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells. Life Sci 2020;256:118005. [PMID: 32593711 DOI: 10.1016/j.lfs.2020.118005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
393 Levin A, Shah NN. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. Am J Hematol 2019;94:S18-23. [PMID: 30652353 DOI: 10.1002/ajh.25403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
394 Kinzel O, Steeneck C, Anderhub S, Hornberger M, Pinto S, Morschhaeuser B, Albers M, Sonnek C, Wang Y, Mallinger A, Czekańska M, Hoffmann T. Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold. Bioorganic & Medicinal Chemistry Letters 2021;33:127738. [DOI: 10.1016/j.bmcl.2020.127738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
395 Kim J, Kong JK, Yang W, Cho H, Chay DB, Lee BH, Cho SJ, Hong S, Kim JH. DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. Cancers (Basel) 2018;10:E279. [PMID: 30134578 DOI: 10.3390/cancers10090279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
396 Wei F, Wang D, Wei J, Tang N, Tang L, Xiong F, Guo C, Zhou M, Li X, Li G, Xiong W, Zhang S, Zeng Z. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance. Cell Mol Life Sci 2021;78:173-93. [PMID: 32654036 DOI: 10.1007/s00018-020-03581-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
397 Shrestha B, Wang L, Brey EM, Uribe GR, Tang L. Smart Nanoparticles for Chemo-Based Combinational Therapy. Pharmaceutics 2021;13:853. [PMID: 34201333 DOI: 10.3390/pharmaceutics13060853] [Reference Citation Analysis]
398 Blessin NC, Spriestersbach P, Li W, Mandelkow T, Dum D, Simon R, Hube-Magg C, Lutz F, Viehweger F, Lennartz M, Fraune C, Nickelsen V, Fehrle W, Göbel C, Weidemann S, Clauditz T, Lebok P, Möller K, Steurer S, Izbicki JR, Sauter G, Minner S, Jacobsen F, Luebke AM, Büscheck F, Höflmayer D, Wilczak W, Burandt E, Hinsch A. Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. Cell Oncol (Dordr) 2020;43:421-30. [PMID: 32141029 DOI: 10.1007/s13402-020-00496-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
399 Yau A, Lee J, Chen Y. Nanomaterials for Protein Delivery in Anticancer Applications. Pharmaceutics 2021;13:155. [PMID: 33503889 DOI: 10.3390/pharmaceutics13020155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
400 Borgheti-Cardoso LN, Viegas JSR, Silvestrini AVP, Caron AL, Praça FG, Kravicz M, Bentley MVLB. Nanotechnology approaches in the current therapy of skin cancer. Adv Drug Deliv Rev 2020;153:109-36. [PMID: 32113956 DOI: 10.1016/j.addr.2020.02.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
401 Yoshida K, Okamoto M, Sasaki J, Kuroda C, Ishida H, Ueda K, Ideta H, Kamanaka T, Sobajima A, Takizawa T, Tanaka M, Aoki K, Uemura T, Kato H, Haniu H, Saito N. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer 2020;20:25. [PMID: 31914969 DOI: 10.1186/s12885-019-6499-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 20.0] [Reference Citation Analysis]
402 George EV, Kalen JE, Kapil JP, Motaparthi K. Comparison of the Inflammatory Infiltrates in Tumoral Melanosis, Regressing Nevi, and Regressing Melanoma. Am J Dermatopathol 2019;41:480-7. [PMID: 30601204 DOI: 10.1097/DAD.0000000000001346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
403 Saglam O, Conejo-Garcia J. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 2018;5. [PMID: 29955379 DOI: 10.15761/ICST.1000272] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
404 Tooyserkani R, Rasaee MJ, Bandehpour M, W P M Löwik D. Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity. J Drug Target 2021;29:771-82. [PMID: 33478285 DOI: 10.1080/1061186X.2021.1879087] [Reference Citation Analysis]
405 Zhang L, Sorensen MD, Kristensen BW, Reifenberger G, McIntyre TM, Lin F. D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells. Clin Cancer Res 2018;24:5381-91. [PMID: 30006485 DOI: 10.1158/1078-0432.CCR-17-3855] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
406 Ou X, Ma Q, Yin W, Ma X, He Z. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More. Front Cell Dev Biol 2021;9:674467. [PMID: 34095145 DOI: 10.3389/fcell.2021.674467] [Reference Citation Analysis]
407 Liu C, Seeram NP, Ma H. Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. Cancer Cell Int 2021;21:239. [PMID: 33906641 DOI: 10.1186/s12935-021-01946-4] [Reference Citation Analysis]
408 Tatiparti K, Rauf MA, Sau S, Iyer AK. Carbonic Anhydrase-IX Guided Albumin Nanoparticles for Hypoxia-mediated Triple-Negative Breast Cancer Cell Killing and Imaging of Patient-derived Tumor. Molecules 2020;25:E2362. [PMID: 32438691 DOI: 10.3390/molecules25102362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
409 He H, Shi L, Meng D, Zhou H, Ma J, Wu Y, Wu Y, Gu Y, Xie W, Zhang J, Zhu Y. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner. Cancer Treat Res Commun 2021;28:100379. [PMID: 33951555 DOI: 10.1016/j.ctarc.2021.100379] [Reference Citation Analysis]
410 Promsote W, DeMouth ME, Almasri CG, Pegu A. Anti-HIV-1 Antibodies: An Update. BioDrugs 2020;34:121-32. [PMID: 32152957 DOI: 10.1007/s40259-020-00413-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
411 Zhang J, Wang L. The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review. Technol Cancer Res Treat 2019;18:1533033819831068. [PMID: 30798772 DOI: 10.1177/1533033819831068] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 26.0] [Reference Citation Analysis]
412 Principe DR, Chiec L, Mohindra NA, Munshi HG. Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. Front Oncol 2021;11:684098. [PMID: 34141625 DOI: 10.3389/fonc.2021.684098] [Reference Citation Analysis]
413 Brennan S, Baird AM, O'Regan E, Sheils O. The Role of Human Papilloma Virus in Dictating Outcomes in Head and Neck Squamous Cell Carcinoma. Front Mol Biosci 2021;8:677900. [PMID: 34250016 DOI: 10.3389/fmolb.2021.677900] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
414 Luo S, Long H, Lu Q. Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus. Int Immunopharmacol 2020;89:107028. [PMID: 33039962 DOI: 10.1016/j.intimp.2020.107028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
415 Yong H, Fu J, Gao G, Shi H, Zheng D, Zhou X. MiR-34a suppresses the proliferation and invasion of gastric cancer by modulating PDL1 in the immune microenvironment. Molecular and Cellular Probes 2020;53:101601. [DOI: 10.1016/j.mcp.2020.101601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
416 Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol 2017;10:174. [PMID: 29195503 DOI: 10.1186/s13045-017-0541-9] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 12.5] [Reference Citation Analysis]
417 Feng Q, Li L, Li M, Wang X. Immunological classification of gliomas based on immunogenomic profiling. J Neuroinflammation 2020;17:360. [PMID: 33246490 DOI: 10.1186/s12974-020-02030-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
418 Castagnoli L, De Santis F, Volpari T, Vernieri C, Tagliabue E, Di Nicola M, Pupa SM. Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure. Cells 2020;9:E555. [PMID: 32120774 DOI: 10.3390/cells9030555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
419 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Reference Citation Analysis]
420 Suliman AM, Bek SA, Elkhatim MS, Husain AA, Mismar AY, Eldean MZS, Lengyel Z, Elazzazy S, Rasul KI, Omar NE. Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review. Cancer Immunol Immunother 2021;70:935-44. [PMID: 33070259 DOI: 10.1007/s00262-020-02726-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
421 Ma R, Yi B, Riker AI, Xi Y. Metformin and cancer immunity. Acta Pharmacol Sin 2020;41:1403-9. [PMID: 32868904 DOI: 10.1038/s41401-020-00508-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
422 Sattiraju A, Mintz A. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions. Adv Exp Med Biol 2019;1147:65-91. [PMID: 31147872 DOI: 10.1007/978-3-030-16908-4_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
423 Chen X, Du Z, Huang M, Wang D, Fong WP, Liang J, Fan L, Wang Y, Yang H, Chen Z, Hu M, Xu R, Li Y. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection. Cancer Immunol Immunother 2021. [PMID: 34322779 DOI: 10.1007/s00262-021-03021-3] [Reference Citation Analysis]
424 Kuchar M, Strizova Z, Capkova L, Komarc M, Skrivan J, Bartunkova J, Smrz D, Plzak J. The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay. Biomedicines 2021;9:97. [PMID: 33498270 DOI: 10.3390/biomedicines9020097] [Reference Citation Analysis]
425 Zhao Y, Liu L, Weng L. Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Front Pharmacol 2021;12:714483. [PMID: 34305619 DOI: 10.3389/fphar.2021.714483] [Reference Citation Analysis]
426 Sati N, Boyne DJ, Cheung WY, Cash SB, Arora P. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. JAMA Netw Open 2021;4:e2034201. [PMID: 33496794 DOI: 10.1001/jamanetworkopen.2020.34201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Xu P, Liang F. Nanomaterial-Based Tumor Photothermal Immunotherapy. Int J Nanomedicine 2020;15:9159-80. [PMID: 33244232 DOI: 10.2147/IJN.S249252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
428 Trung LQ, An DTT. Is Resveratrol a Cancer Immunomodulatory Molecule? Front Pharmacol 2018;9:1255. [PMID: 30459616 DOI: 10.3389/fphar.2018.01255] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
429 Nabil G, Alzhrani R, Alsaab HO, Atef M, Sau S, Iyer AK, Banna HE. CD44 Targeted Nanomaterials for Treatment of Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:898. [PMID: 33672756 DOI: 10.3390/cancers13040898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Brown HK, Schiavone K, Gouin F, Heymann MF, Heymann D. Biology of Bone Sarcomas and New Therapeutic Developments. Calcif Tissue Int 2018;102:174-95. [PMID: 29238848 DOI: 10.1007/s00223-017-0372-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
431 Kowalski A, Malinowska K, Olszewski J, Zielińska-Bliźniewska H. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer. Biomolecules 2021;11:970. [PMID: 34356594 DOI: 10.3390/biom11070970] [Reference Citation Analysis]
432 Cordonnier M, Nardin C, Chanteloup G, Derangere V, Algros MP, Arnould L, Garrido C, Aubin F, Gobbo J. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles 2020;9:1710899. [PMID: 32002173 DOI: 10.1080/20013078.2019.1710899] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 43.0] [Reference Citation Analysis]
433 Luo Q, Zhang L, Luo C, Jiang M. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett 2019;454:191-203. [PMID: 30998963 DOI: 10.1016/j.canlet.2019.04.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
434 Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, Zhang H. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Adv Drug Deliv Rev 2021;:113891. [PMID: 34324887 DOI: 10.1016/j.addr.2021.113891] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
435 Jiang Q, Ghafoor A, Mian I, Rathkey D, Thomas A, Alewine C, Sengupta M, Ahlman MA, Zhang J, Morrow B, Steinberg SM, Pastan I, Hassan R. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci Transl Med 2020;12:eaaz7252. [PMID: 32611684 DOI: 10.1126/scitranslmed.aaz7252] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
436 Mulligan LM. GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential. Front Physiol 2018;9:1873. [PMID: 30666215 DOI: 10.3389/fphys.2018.01873] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
437 Gaucher L, Adda L, Séjourné A, Joachim C, Guillaume C, Poulet C, Liabeuf S, Gras-Champel V, Masmoudi K, Houessinon A, Bennis Y, Batteux B. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol 2021;13:17588359211000591. [PMID: 33796151 DOI: 10.1177/17588359211000591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Rossi JF, Céballos P, Lu ZY. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Commun (Lond) 2019;39:34. [PMID: 31200766 DOI: 10.1186/s40880-019-0379-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 17.5] [Reference Citation Analysis]
439 Samir A, Tawab RA, Eltayebi HM. Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes. Oncol Lett 2021;22:593. [PMID: 34149904 DOI: 10.3892/ol.2021.12854] [Reference Citation Analysis]
440 Martini A, Fallara G, Pellegrino F, Cirulli GO, Larcher A, Necchi A, Montorsi F, Capitanio U. Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. World J Urol 2021;39:1369-76. [PMID: 33386494 DOI: 10.1007/s00345-020-03550-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
441 Kruziki MA, Sarma V, Hackel BJ. Constrained Combinatorial Libraries of Gp2 Proteins Enhance Discovery of PD-L1 Binders. ACS Comb Sci 2018;20:423-35. [PMID: 29799714 DOI: 10.1021/acscombsci.8b00010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
442 Laphanuwat P, Jirawatnotai S. Immunomodulatory Roles of Cell Cycle Regulators. Front Cell Dev Biol 2019;7:23. [PMID: 30863749 DOI: 10.3389/fcell.2019.00023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
443 Drakes ML, Czerlanis CM, Stiff PJ. Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. Cancers (Basel) 2020;12:E3301. [PMID: 33182298 DOI: 10.3390/cancers12113301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
444 Filipovic A, Miller G, Bolen J. Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. Front Cell Dev Biol 2020;8:155. [PMID: 32258034 DOI: 10.3389/fcell.2020.00155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
445 Nguyen ED, Xue YK, Danesh M, Ameri A, Weng CQ, Klebanov N, Foreman RK, Nazarian RM, Demehri S, Tsao H, Kroshinsky D. A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies. Dermatopathology (Basel) 2019;6:255-9. [PMID: 32232031 DOI: 10.1159/000505353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
446 Giannicola R, D'Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Nardone V, Monoriti M, Calabrese G, Tripepi G, Pirtoli L, Tassone P, Tagliaferri P, Correale P. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. Mol Clin Oncol 2019;11:81-90. [PMID: 31289683 DOI: 10.3892/mco.2019.1859] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
447 Cusato J, Genova C, Tomasello C, Carrega P, Ottonello S, Pietra G, Mingari MC, Cossu I, Rijavec E, Leggieri A, Di Perri G, Dal Bello MG, Coco S, Boccardo S, Ferlazzo G, Grossi F, D'Avolio A. Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers (Basel) 2019;11:E125. [PMID: 30669662 DOI: 10.3390/cancers11010125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
448 Yang Y, Wang K, Chen H, Feng Z. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction. Eur J Med Chem 2021;211:113001. [PMID: 33272783 DOI: 10.1016/j.ejmech.2020.113001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
449 Fu R, Jing CQ, Li XR, Tan ZF, Li HJ. Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy. Cancer Manag Res 2021;13:4935-46. [PMID: 34188546 DOI: 10.2147/CMAR.S312690] [Reference Citation Analysis]
450 Sachdev JC, Sandoval AC, Jahanzeb M. Update on Precision Medicine in Breast Cancer. Cancer Treat Res 2019;178:45-80. [PMID: 31209841 DOI: 10.1007/978-3-030-16391-4_2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
451 Longo F, Perri F, Caponigro F, Della Vittoria Scarpati G, Guida A, Pavone E, Aversa C, Muto P, Giuliano M, Ionna F, Solla R. Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck? Cancers (Basel) 2020;12:E2781. [PMID: 32998297 DOI: 10.3390/cancers12102781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
452 Abunasser AAA, Xue J, Balawi EJA, Zhu Y. Combination of the EP and Anti-PD-1 Pathway or Anti-CTLA-4 for the Phase III Trial of Small-Cell Lung Cancer: A Meta-Analysis. J Oncol 2021;2021:6662344. [PMID: 34122547 DOI: 10.1155/2021/6662344] [Reference Citation Analysis]
453 Hager S, Fittler FJ, Wagner E, Bros M. Nucleic Acid-Based Approaches for Tumor Therapy. Cells 2020;9:E2061. [PMID: 32917034 DOI: 10.3390/cells9092061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
454 Cimadamore A, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. Curr Drug Metab 2019;20:305-12. [PMID: 30799789 DOI: 10.2174/1389200220666190225124352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
455 Shivaji UN, Jeffery L, Gui X, Smith SCL, Ahmad OF, Akbar A, Ghosh S, Iacucci M. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol 2019;12:1756284819884196. [PMID: 31723355 DOI: 10.1177/1756284819884196] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
456 Liu YJ, Tsang NM, Hsueh C, Yeh CJ, Ueng SH, Wang TH, Chuang WY. Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy. Cancers (Basel) 2018;10:E374. [PMID: 30304846 DOI: 10.3390/cancers10100374] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
457 Käsmann L, Eze C, Taugner J, Roengvoraphoj O, Dantes M, Schmidt-Hegemann NS, Schiopu S, Belka C, Manapov F. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol 2020;15:167. [PMID: 32646443 DOI: 10.1186/s13014-020-01595-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
458 Garcia D, Nasarre P, Bonilla IV, Hilliard E, Peterson YK, Spruill L, Broome AM, Hill EG, Yustein JT, Mehrotra S, Klauber-DeMore N. Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo. Ann Surg Oncol 2019;26:4782-90. [PMID: 31515721 DOI: 10.1245/s10434-019-07800-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
459 Deng H, Zhang Z. The application of nanotechnology in immune checkpoint blockade for cancer treatment. J Control Release 2018;290:28-45. [PMID: 30287266 DOI: 10.1016/j.jconrel.2018.09.026] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
460 Zhao Z, Bai H, Duan J, Wang J. Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic. Thorac Cancer. 2020;11:1752-1757. [PMID: 32291968 DOI: 10.1111/1759-7714.13424] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
461 Yasunaga M, Manabe S, Tsuji A, Furuta M, Ogata K, Koga Y, Saga T, Matsumura Y. Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging. Bioengineering (Basel) 2017;4:E78. [PMID: 28952557 DOI: 10.3390/bioengineering4030078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
462 Yang F, Shi K, Jia YP, Hao Y, Peng JR, Qian ZY. Advanced biomaterials for cancer immunotherapy. Acta Pharmacol Sin 2020;41:911-27. [PMID: 32123302 DOI: 10.1038/s41401-020-0372-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
463 Shui L, Yang X, Li J, Yi C, Sun Q, Zhu H. Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy.Front Immunol. 2019;10:2989. [PMID: 32010123 DOI: 10.3389/fimmu.2019.02989] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
464 Djurian A, Makino T, Lim Y, Sengoku S, Kodama K. Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents. J Pers Med 2021;11:460. [PMID: 34073680 DOI: 10.3390/jpm11060460] [Reference Citation Analysis]
465 Gauckler P, Leierer J, Kocher F, Feistritzer C, Willenbacher W, Gunsilius E, Wolf D, Neuwirt H, Mayer G, Kronbichler A. Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma-A case report. J Clin Apher 2020;35:227-30. [PMID: 32142176 DOI: 10.1002/jca.21775] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
466 Markham A, Keam SJ. Camrelizumab: First Global Approval. Drugs. 2019;79:1355-1361. [PMID: 31313098 DOI: 10.1007/s40265-019-01167-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 22.5] [Reference Citation Analysis]
467 Lu CS, Lin CW, Chang YH, Chen HY, Chung WC, Lai WY, Ho CC, Wang TH, Chen CY, Yeh CL, Wu S, Wang SP, Yang PC. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. J Immunother Cancer 2020;8:e001392. [PMID: 33243934 DOI: 10.1136/jitc-2020-001392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
468 Zito Marino F, Rossi G, Montella M, Botti G, De Cecio R, Morabito A, La Manna C, Ronchi A, Micheli M, Salatiello G, Micheli P, Rocco D, Accardo M, Franco R. Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. American Journal of Surgical Pathology 2020;44:378-86. [DOI: 10.1097/pas.0000000000001400] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
469 Marzagalli M, Fontana F, Raimondi M, Limonta P. Cancer Stem Cells-Key Players in Tumor Relapse. Cancers (Basel) 2021;13:376. [PMID: 33498502 DOI: 10.3390/cancers13030376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
470 Langhans SA. Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. Front Pharmacol. 2018;9:6. [PMID: 29410625 DOI: 10.3389/fphar.2018.00006] [Cited by in Crossref: 408] [Cited by in F6Publishing: 306] [Article Influence: 136.0] [Reference Citation Analysis]
471 Broos K, Lecocq Q, Xavier C, Bridoux J, Nguyen TT, Corthals J, Schoonooghe S, Lion E, Raes G, Keyaerts M, Devoogdt N, Breckpot K. Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. Cancers (Basel) 2019;11:E872. [PMID: 31234464 DOI: 10.3390/cancers11060872] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
472 Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, Vincenzi B, Calò V, Iovanna JL, Bazan V, Russo A. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Cell Immunol 2019;343:103753. [PMID: 29395859 DOI: 10.1016/j.cellimm.2018.01.013] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 22.7] [Reference Citation Analysis]
473 Parmar V, Nair NS, Thakkar P, Chitkara G. Molecular Biology in the Breast Clinics-Current status and future perspectives. Indian J Surg Oncol 2021;12:7-20. [PMID: 33994723 DOI: 10.1007/s13193-019-00954-1] [Reference Citation Analysis]
474 Yuan C, Liu Y, Wang T, Sun M, Chen X. Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy. ACS Biomater Sci Eng 2020;6:4774-98. [DOI: 10.1021/acsbiomaterials.0c00804] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
475 Steven A, Seliger B. The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. Breast Care (Basel) 2018;13:16-21. [PMID: 29950962 DOI: 10.1159/000486585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 11.3] [Reference Citation Analysis]
476 De Las Casas LE, Hicks DG. Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing. Am J Clin Pathol 2021;155:781-92. [PMID: 33582767 DOI: 10.1093/ajcp/aqaa212] [Reference Citation Analysis]
477 Sell S, Ilic Z. Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty. Tumour Biol 2019;41:1010428319873749. [PMID: 31496424 DOI: 10.1177/1010428319873749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
478 Huang W, He L, Ouyang J, Chen Q, Liu C, Tao W, Chen T. Triangle-Shaped Tellurium Nanostars Potentiate Radiotherapy by Boosting Checkpoint Blockade Immunotherapy. Matter 2020;3:1725-53. [DOI: 10.1016/j.matt.2020.08.027] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 18.0] [Reference Citation Analysis]
479 Drakes ML, Stiff PJ. Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. Adv Exp Med Biol 2021;1330:33-54. [PMID: 34339029 DOI: 10.1007/978-3-030-73359-9_3] [Reference Citation Analysis]
480 Jiao P, Geng Q, Jin P, Su G, Teng H, Dong J, Yan B. Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy. Curr Pharm Des 2018;24:4911-20. [PMID: 30417781 DOI: 10.2174/1381612824666181112114958] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
481 Offeddu GS, Haase K, Gillrie MR, Li R, Morozova O, Hickman D, Knutson CG, Kamm RD. An on-chip model of protein paracellular and transcellular permeability in the microcirculation. Biomaterials 2019;212:115-25. [PMID: 31112823 DOI: 10.1016/j.biomaterials.2019.05.022] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
482 Parylo S, Vennepureddy A, Dhar V, Patibandla P, Sokoloff A. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment. J Oncol Pharm Pract 2019;25:110-29. [PMID: 29726787 DOI: 10.1177/1078155218770904] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
483 Huelse JM, Fridlyand DM, Earp S, DeRyckere D, Graham DK. MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacol Ther 2020;213:107577. [PMID: 32417270 DOI: 10.1016/j.pharmthera.2020.107577] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
484 Prabhash K, Advani SH, Batra U, Biswas B, Chougule A, Ghosh M, Muddu VK, Sahoo TP, Vaid AK. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing. Adv Ther 2019;36:766-85. [PMID: 30864106 DOI: 10.1007/s12325-019-00903-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
485 Liang H, Lin G, Wang W, Huang J, Yang Y, Lan Y, Wang R, Cui F, Hao Z, Deng H, Zhao S, Cheng B, Xiong S, Li J, Li C, Liu J, He J, Liang W. Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis. Transl Lung Cancer Res 2020;9:188-203. [PMID: 32420059 DOI: 10.21037/tlcr.2020.02.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
486 Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 2019;234:1313-1325. [PMID: 30191996 DOI: 10.1002/jcp.27172] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 23.3] [Reference Citation Analysis]
487 Nhokaew W, Kleebkaow P, Chaisuriya N, Kietpeerakool C. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors. Asian Pac J Cancer Prev 2019;20:1161-9. [PMID: 31030490 DOI: 10.31557/APJCP.2019.20.4.1161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
488 Nakamura K, Okuyama R, Kawakami Y. Renin-Angiotensin System in the Tumor Microenvironment. Adv Exp Med Biol 2020;1277:105-14. [PMID: 33119868 DOI: 10.1007/978-3-030-50224-9_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
489 Zhou X, Qu M, Tebon P, Jiang X, Wang C, Xue Y, Zhu J, Zhang S, Oklu R, Sengupta S, Sun W, Khademhosseini A. Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. Adv Sci (Weinh) 2020;7:2001447. [PMID: 33042756 DOI: 10.1002/advs.202001447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
490 Yoo B, Fuchs BC, Medarova Z. New Directions in the Study and Treatment of Metastatic Cancer. Front Oncol 2018;8:258. [PMID: 30042926 DOI: 10.3389/fonc.2018.00258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
491 Noé V, Aubets E, Félix AJ, Ciudad CJ. Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins. Biochem Pharmacol 2021;189:114371. [PMID: 33338475 DOI: 10.1016/j.bcp.2020.114371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
492 Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Front Pharmacol. 2018;9:185. [PMID: 29556198 DOI: 10.3389/fphar.2018.00185] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 45.0] [Reference Citation Analysis]
493 Wang YG, Zheng DH, Shi M, Xu XM. T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. J Med Genet 2019;56:22-8. [PMID: 30518547 DOI: 10.1136/jmedgenet-2018-105570] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
494 Shen C, Wei W, Lin L. Diterpenoids and Bisnorditerpenoids from Blumea aromatica. J Nat Prod 2019;82:3181-5. [DOI: 10.1021/acs.jnatprod.9b00674] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
495 Sau S, Iyer AK. Immunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients. J Thorac Dis 2018;10:4682-5. [PMID: 30233838 DOI: 10.21037/jtd.2018.07.66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
496 Kouzel Martinez F, Graffeo CS, Carlstrom LP, Link MJ. Growth arrest of a refractory vestibular schwannoma after anti-PD-1 antibody treatment. BMJ Case Rep 2021;14:e241834. [PMID: 34045200 DOI: 10.1136/bcr-2021-241834] [Reference Citation Analysis]
497 Erlendsson AM, Olesen UH, Haedersdal M, Rossi AM. Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors-Clinical review and future perspectives. Adv Drug Deliv Rev 2020;153:185-94. [PMID: 31923431 DOI: 10.1016/j.addr.2020.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
498 Golay J, Andrea AE. Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies (Basel) 2020;9:E17. [PMID: 32443877 DOI: 10.3390/antib9020017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
499 Lakatos E, Williams MJ, Schenck RO, Cross WCH, Househam J, Zapata L, Werner B, Gatenbee C, Robertson-Tessi M, Barnes CP, Anderson ARA, Sottoriva A, Graham TA. Evolutionary dynamics of neoantigens in growing tumors. Nat Genet 2020;52:1057-66. [PMID: 32929288 DOI: 10.1038/s41588-020-0687-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
500 Yang Y, Hecht JR, Liu ST, Cohen MJ, Hart SD, Wang HL, Heaney AP. CAUTION ADVISED USING COMBINATION KETOCONAZOLE AND PD-1 INHIBITORS. AACE Clin Case Rep 2020;6:e239-42. [PMID: 32984529 DOI: 10.4158/ACCR-2020-0100] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
501 Stanland LJ, Luftig MA. Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer. Future Virol 2018;13:803-18. [PMID: 34367314 DOI: 10.2217/fvl-2018-0071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
502 Deng M, Guo R, Zang S, Rao J, Li M, Tang X, Xia C, Li M, Zhang Z, He Q. pH-Triggered Copper-Free Click Reaction-Mediated Micelle Aggregation for Enhanced Tumor Retention and Elevated Immuno-Chemotherapy against Melanoma. ACS Appl Mater Interfaces 2021;13:18033-46. [PMID: 33834754 DOI: 10.1021/acsami.1c02567] [Reference Citation Analysis]
503 Siddiqui S, Denlinger LC, Fowler SJ, Akuthota P, Shaw DE, Heaney LG, Brown L, Castro M, Winders TA, Kraft M, Wagers S, Peters MC, Pavord ID, Walker S, Jarjour NN. Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. Am J Respir Crit Care Med 2019;199:823-9. [PMID: 30726120 DOI: 10.1164/rccm.201809-1817PP] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 21.0] [Reference Citation Analysis]
504 Jin J, Zhao Q. Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges. J Nanobiotechnology 2020;18:75. [PMID: 32408880 DOI: 10.1186/s12951-020-00629-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
505 Zaslavsky AB, Adams MP, Cao X, Maj T, Choi JE, Stangl-Kremser J, Patel S, Putelo A, Lee SK, Nallandhighal S, Kasputis A, Alva A, Lew M, Qin A, Mehra R, Morgan TM, Salami SS, Reichert Z, Udager A, Zou W, Palapattu GS. Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. Sci Rep 2020;10:19296. [PMID: 33168847 DOI: 10.1038/s41598-020-76351-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
506 Wang G, Wang L, Zhou J, Xu X. The Possible Role of PD-1 Protein in Ganoderma lucidum-Mediated Immunomodulation and Cancer Treatment. Integr Cancer Ther 2019;18:1534735419880275. [PMID: 31595795 DOI: 10.1177/1534735419880275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
507 Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, Shin JI, Gamerith G. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1798. [PMID: 31731749 DOI: 10.3390/cancers11111798] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 15.5] [Reference Citation Analysis]
508 Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. J Natl Cancer Inst 2020;112:562-73. [PMID: 32145020 DOI: 10.1093/jnci/djaa021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
509 Vukadin S, Khaznadar F, Kizivat T, Vcev A, Smolic M. Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update. Biomedicines 2021;9:835. [PMID: 34356899 DOI: 10.3390/biomedicines9070835] [Reference Citation Analysis]
510 Konieczny M, Musielak B, Kocik J, Skalniak L, Sala D, Czub M, Magiera-Mularz K, Rodriguez I, Myrcha M, Stec M, Siedlar M, Holak TA, Plewka J. Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint. J Med Chem 2020;63:11271-85. [PMID: 32936638 DOI: 10.1021/acs.jmedchem.0c01260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
511 Principe DR, Park A, Dorman MJ, Kumar S, Viswakarma N, Rubin J, Torres C, McKinney R, Munshi HG, Grippo PJ, Rana A. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer. Mol Cancer Ther 2019;18:613-20. [PMID: 30587556 DOI: 10.1158/1535-7163.MCT-18-0850] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 14.0] [Reference Citation Analysis]
512 Maamari J, Yeung SJ, Chaftari PS. Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am J Emerg Med 2019;37:376.e1-2. [PMID: 30361152 DOI: 10.1016/j.ajem.2018.10.040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
513 Tuccilli C, Baldini E, Sorrenti S, Catania A, Antonelli A, Fallahi P, Tartaglia F, Barollo S, Mian C, Palmieri A, Carbotta G, Arcieri S, Pironi D, Vergine M, Monti M, Ulisse S. CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers. Int J Endocrinol 2018;2018:1742951. [PMID: 30123257 DOI: 10.1155/2018/1742951] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
514 Sau S, Alzhrani R, Bhise K, Alsaab HO, Kashaw SK, Iyer AK. Nanomaterials for tumor immunomodulation and overcoming current clinical challenges. Nanomedicine 2019;14:1515-9. [DOI: 10.2217/nnm-2019-0109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
515 Onitilo AA, Wittig JA. Principles of Immunotherapy in Melanoma.Surg Clin North Am. 2020;100:161-173. [PMID: 31753110 DOI: 10.1016/j.suc.2019.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
516 Ahdoot M, Theodorescu D. Immunotherapy of high risk non-muscle invasive bladder cancer. Expert Rev Clin Pharmacol 2021. [PMID: 34187272 DOI: 10.1080/17512433.2021.1950531] [Reference Citation Analysis]
517 Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood 2018;132:2484-94. [PMID: 30275109 DOI: 10.1182/blood-2018-05-849802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
518 Zhang H, Liu K, Pu Q, Achab A, Ardolino MJ, Cheng M, Deng Y, Doty AC, Ferguson H, Fradera X, Knemeyer I, Kurukulasuriya R, Lam YH, Lesburg CA, Martinot TA, McGowan MA, Miller JR, Otte K, Biju PJ, Sciammetta N, Solban N, Yu W, Zhou H, Wang X, Bennett DJ, Han Y. Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy. ACS Med Chem Lett 2019;10:1530-6. [PMID: 31749906 DOI: 10.1021/acsmedchemlett.9b00344] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
519 Zhao L, Cao Y. PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer. Dis Markers 2020;2020:8843146. [PMID: 33062072 DOI: 10.1155/2020/8843146] [Reference Citation Analysis]
520 Taghizadeh H, Marhold M, Tomasich E, Udovica S, Merchant A, Krainer M. Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives. Oncoimmunology 2019;8:e1644109. [PMID: 31646092 DOI: 10.1080/2162402X.2019.1644109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
521 Cioccoloni G, Aquino A, Notarnicola M, Caruso MG, Bonmassar E, Zonfrillo M, Caporali S, Faraoni I, Villivà C, Fuggetta MP, Franzese O. Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line. J Chemother 2020;32:30-40. [PMID: 31775585 DOI: 10.1080/1120009X.2019.1694761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
522 Vallejo-Ardila DL, Fifis T, Burrell LM, Walsh K, Christophi C. Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity. Oncotarget 2018;9:35500-11. [PMID: 30464806 DOI: 10.18632/oncotarget.26174] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
523 Peng S, Tan M, Li YD, Cheng MA, Farmer E, Ferrall L, Gaillard S, Roden RBS, Hung CF, Wu TC. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. Cancer Immunol Immunother 2021;70:1049-62. [PMID: 33108473 DOI: 10.1007/s00262-020-02754-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
524 Antomarchi J, Ambrosetti D, Cohen C, Delotte J, Chevallier A, Karimdjee-Soilihi B, Ngo-Mai M, Schmid-Alliana A, Schmid-Antomarchi H. Immunosuppressive Tumor Microenvironment Status and Histological Grading of Endometrial Carcinoma. Cancer Microenviron 2019;12:169-79. [PMID: 31134527 DOI: 10.1007/s12307-019-00225-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
525 Dai Z, Zhang J, Wu Q, Fang H, Shi C, Li Z, Lin C, Tang D, Wang D. Intestinal microbiota: a new force in cancer immunotherapy. Cell Commun Signal 2020;18:90. [PMID: 32522267 DOI: 10.1186/s12964-020-00599-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
526 Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, Yang X. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug Des Devel Ther 2020;14:3625-49. [PMID: 32982171 DOI: 10.2147/DDDT.S267433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
527 Tiemann M, Samoilova V, Atiakshin D, Buchwalow I. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. BMC Res Notes 2020;13:139. [PMID: 32143684 DOI: 10.1186/s13104-020-04975-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
528 Reddy HG, Schneider BJ, Tai AW. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. Clin Transl Gastroenterol. 2018;9:180. [PMID: 30228268 DOI: 10.1038/s41424-018-0049-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
529 Chu TH, Vo MC, Park HS, Lakshmi TJ, Jung SH, Kim HJ, Lee JJ. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma. Cancer Immunol Immunother 2021;70:31-45. [PMID: 32623477 DOI: 10.1007/s00262-020-02654-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
530 Wang Y, Liu X, Wang X, Zheng W, Zhang J, Shi F, Liu J. Redox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatment. Sci Rep 2018;8:12968. [PMID: 30154488 DOI: 10.1038/s41598-018-29692-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
531 Ren D, Hua Y, Yu B, Ye X, He Z, Li C, Wang J, Mo Y, Wei X, Chen Y, Zhou Y, Liao Q, Wang H, Xiang B, Zhou M, Li X, Li G, Li Y, Zeng Z, Xiong W. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer 2020;19:19. [PMID: 32000802 DOI: 10.1186/s12943-020-1144-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 51.0] [Reference Citation Analysis]
532 Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK. Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer 2019;125:3234-41. [DOI: 10.1002/cncr.32206] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
533 Bleve A, Durante B, Sica A, Consonni FM. Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. Int J Mol Sci 2020;21:E5845. [PMID: 32823961 DOI: 10.3390/ijms21165845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
534 Yasuoka H, Asai A, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis. Sci Rep 2020;10:10377. [PMID: 32587357 DOI: 10.1038/s41598-020-67497-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
535 Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Front Immunol 2018;9:394. [PMID: 29599770 DOI: 10.3389/fimmu.2018.00394] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 17.7] [Reference Citation Analysis]